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Abstract 
Glaucoma is an irreversible disease affecting the eye, leading to progressive loss of vision and 
eventually to total blindness. It is often related to high intraocular pressure (IOP), which 
results from increased outflow resistance to aqueous humor. The first line of treatment to stop 
or slow down the progression of the disease is based on medication, but when this fails one 
has to resort to invasive methods, such as filtering surgery. Filtering surgery, including 
drainage implants or aqueous shunts, aims in reducing intraocular pressure by creating an 
additional outflow conduit to aqueous humor. However, even if filtering surgery is effective 
in lowering intraocular pressure, it is often associated with several complications that could 
potentially lead to further damages impairing the sight. The origin of most complications can 
be traced to a fundamental mechanism: poor flow control. Among others, hypotony (IOP < 5 
mmHg) is one of the most frequent complications after glaucoma filtering surgery. Hypotony 
is a consequence of very low outflow resistance, leading in some severe cases to anterior 
chamber flattening or choroidal detachment, among others. Consequently, modifications to 
glaucoma drainage devices and new surgical techniques were developed to minimize the rates 
of early post-operative hypotony. Unfortunately, these techniques are poorly reproducible and 
not fully predictable. At present, there are no real alternatives at hand to clearly improve the 
success rate of filtering surgery outcomes. 
In view of the aforementioned problems related to filtering surgery, a new glaucoma drainage 
device has been developed. This draining implant has the same function like any of the 
current drainage devices but with the specific additional feature of an adjustable resistor to the 
aqueous humor egress. The device is non-invasively adjustable allowing for a non-traumatic 
change of the resistance during the entire post-operative period. In vitro tests realized on 
enucleated rabbit eyes and in vivo tests on rabbits have shown the efficacy of the implant in 
reducing the pressure by selectively adjusting the resistor. Biocompatibility tests have also 
been performed to ensure the safety of the device for human use. The ease of use and the 
reproducibility of the measurements indicate that the novel implant can be potentially of great 
utility in filtering surgery, offering great flow control, reducing complications rates and 
leading to better clinical outcomes. 
Keywords 
Glaucoma; filtering surgery; aqueous shunt; glaucoma drainage device; aqueous humor.  
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Résumé 
Le glaucome est une maladie irréversible qui affecte l’œil et qui conduit progressivement à 
une perte de vue voire même à la cécité. Il est souvent associé à une haute pression 
intraoculaire (PIO), qui résulte d’une augmentation de la résistance à l’écoulement de 
l’humeur aqueuse. Le premier type de traitement pour stopper ou freiner la progression de 
cette maladie repose sur des médicaments, mais quant ceux-ci ne sont pas suffisants, il faut 
envisager des méthodes plus invasives comme la chirurgie filtrante. La chirurgie filtrante, qui 
inclut l’utilisation d’implants de drainage, a pour but de réduire la PIO en créant une voie 
d’écoulement additionnel à l’humeur aqueuse. Néanmoins, même si cette méthode est 
efficace pour réduire la pression intraoculaire, elle est associée à un nombre non négligeable 
de complications qui peuvent potentiellement conduire à des dommages affectant la vue du 
patient. L’origine de ces complications a comme dénominateur commun un manque de 
contrôle dans l’écoulement de l’humeur aqueuse. Parmi d’autres, l’hypotonie (PIO ≤ 5 
mmHg) est l’une des complications les plus fréquentes liée à la chirurgie filtrante. 
L’hypotonie est due à une résistance d’écoulement trop petite conduisant dans des cas 
extrêmes au décollement de la choroïde ou à une chambre aplatie, par exemple. Par 
conséquent plusieurs modifications ont été apportées aux implants de drainage et de nouvelles 
méthodes ont été développées afin de minimiser le taux d’hypotonie post-opératoire. 
Malheureusement, ces techniques sont peu reproductibles et peu prévisibles. Actuellement, il 
n’y a pas de réelle alternative à disposition pour améliorer le taux de succès du devenir d’une 
chirurgie filtrante.  
En relation avec les problèmes liés à la chirurgie filtrante cités ci-dessus, un nouvel implant 
de drainage pour le glaucome a été développé. Cet implant obéit au même concept que les 
implants existants actuellement, mais avec l’addition d’une résistance modulable à 
l’écoulement de l’humeur aqueuse. Ce dispositif est ajustable non invasiment ce qui permet 
un réglage non traumatique de la résistance à l’écoulement tout au long du suivi du patient. 
Des tests in vitro réalisé sur des yeux énucléés de lapins ainsi que des tests in vivo sur des 
lapins, ont montré l’efficacité de l’implant en réduisant la pression de l’œil, en ajustant 
sélectivement la résistance appropriée. Des tests de biocompatibilités ont également démontré 
que l’implant est sûr pour une utilisation humaine. La facilité d’emploi ainsi que la 
reproductibilité des mesures indiquent que ce nouvel implant peut être d’un grand bénéfice 
pour la chirurgie filtrante, en apportant un contrôle effectif sur l’écoulement de l’humeur 
aqueuse, réduisant ainsi les complications et permettant de meilleurs résultats cliniques. 
Mots clés  
Glaucome ; chirurgie filtrante ; implant de drainage ; humeur aqueuse ; pression intraoculaire.  
 
 8 
  
A New Non-Invasively Adjustable Glaucoma Drainage Device	   9 
 
Content 
ACKNOWLEDGMENTS	  ..................................................................................................................................	  3	  
ABSTRACT	  ........................................................................................................................................................	  5	  
KEYWORDS	  ......................................................................................................................................................	  5	  
RÉSUMÉ	  .............................................................................................................................................................	  7	  
CONTENT	  ..........................................................................................................................................................	  9	  
LIST	  OF	  FIGURES	  ..........................................................................................................................................	  11	  
LIST	  OF	  TABLES	  ............................................................................................................................................	  12	  	   :	  INTRODUCTION	  ..............................................................................................................	  13	  CHAPTER	  1
1.1 MOTIVATION ............................................................................................................................. 14 
1.2 GLAUCOMA AND AQUEOUS HUMOR ........................................................................................ 14 
1.3 FILTERING SURGERY ................................................................................................................. 15 
1.4 GLAUCOMA DRAINAGE DEVICES ............................................................................................. 17 
1.5 HYPOTONY ................................................................................................................................ 22 
1.6 TUBE-CORNEA TOUCH .............................................................................................................. 23 
1.7 HYPERTENSIVE PHASE .............................................................................................................. 24 
1.8 REQUIREMENTS FOR NEXT GDD GENERATION ........................................................................ 26 
1.9 REFERENCES ............................................................................................................................. 27 
CHAPTERS	  ......................................................................................................................................................	  31	  
PAPER	  1	  ...........................................................................................................................................................	  31	  
PAPER	  2	  ...........................................................................................................................................................	  31	  
PAPER	  3	  ...........................................................................................................................................................	  32	  
PAPER	  4	  ...........................................................................................................................................................	  33	  	   :	  1ST	  PAPER	  ..........................................................................................................................	  35	  CHAPTER	  2
2.1 INTRODUCTION ......................................................................................................................... 37 
2.2 MATERIAL AND METHODS ....................................................................................................... 39 
2.3 RESULTS ................................................................................................................................... 43 
2.4 DISCUSSION .............................................................................................................................. 50 
2.5 CONCLUSION ............................................................................................................................. 54 
2.6 ACKNOWLEDGEMENTS ............................................................................................................. 56 
2.7 REFERENCES ............................................................................................................................. 57 	   :	  2ND	  PAPER	  .........................................................................................................................	  59	  CHAPTER	  3
3.1 INTRODUCTION ......................................................................................................................... 61 
3.2 MATERIALS AND METHODS ...................................................................................................... 62 
3.3 RESULTS ................................................................................................................................... 66 
3.4 DISCUSSION .............................................................................................................................. 67 
 10 
3.5 ACKNOWLEDGMENTS ............................................................................................................... 70 
3.6 REFERENCES ............................................................................................................................. 71 	   :	  3RD	  PAPER	  .........................................................................................................................	  73	  CHAPTER	  4
4.1 INTRODUCTION ......................................................................................................................... 75 
4.2 METHODS AND MATERIALS ...................................................................................................... 75 
4.3 RESULTS ................................................................................................................................... 78 
4.4 DISCUSSION .............................................................................................................................. 80 
4.5 REFERENCES ............................................................................................................................. 83 	   :	  4TH	  PAPER	  .........................................................................................................................	  85	  CHAPTER	  5
5.1 INTRODUCTION ......................................................................................................................... 87 
5.2 MATERIALS AND METHODS ...................................................................................................... 88 
5.3 RESULTS ................................................................................................................................... 92 
5.4 DISCUSSION .............................................................................................................................. 94 
5.5 ACKNOWLEDGMENTS ............................................................................................................... 99 
5.6 REFERENCES ........................................................................................................................... 100 	   :	  CONCLUSION	  .................................................................................................................	  103	  CHAPTER	  6
PERSPECTIVES	  ...........................................................................................................................................	  105	  
CURRICULUM	  VITAE	  ................................................................................................................................	  106	  
 
 
  
A New Non-Invasively Adjustable Glaucoma Drainage Device	   11 
 
List of Figures 
Figure	  1-­‐1	  .......................................................................................................................................................................................................	  15	  
Figure	  1-­‐2	  .......................................................................................................................................................................................................	  16	  
Figure	  1-­‐3	  .......................................................................................................................................................................................................	  17	  
Figure	  1-­‐4.	  ......................................................................................................................................................................................................	  18	  
Figure	  1-­‐5	  .......................................................................................................................................................................................................	  19	  
Figure	  1-­‐6	  .......................................................................................................................................................................................................	  19	  
Figure	  1-­‐7	  .......................................................................................................................................................................................................	  20	  
Figure	  1-­‐8	  .......................................................................................................................................................................................................	  20	  
Figure	  1-­‐9	  .......................................................................................................................................................................................................	  21	  
Figure	  1-­‐10.	  ....................................................................................................................................................................................................	  23	  
Figure	  2-­‐1	  .......................................................................................................................................................................................................	  40	  
Figure	  2-­‐2	  .......................................................................................................................................................................................................	  44	  
Figure	  2-­‐3	  .......................................................................................................................................................................................................	  45	  
Figure	  2-­‐4.	  ......................................................................................................................................................................................................	  46	  
Figure	  2-­‐5	  .......................................................................................................................................................................................................	  47	  
Figure	  2-­‐6	  .......................................................................................................................................................................................................	  48	  
Figure	  2-­‐7.	  ......................................................................................................................................................................................................	  48	  
Figure	  2-­‐8	  .......................................................................................................................................................................................................	  49	  
Figure	  2-­‐9	  .......................................................................................................................................................................................................	  50	  
Figure	  3-­‐1	  .......................................................................................................................................................................................................	  63	  
Figure	  3-­‐2	  .......................................................................................................................................................................................................	  63	  
Figure	  3-­‐3	  .......................................................................................................................................................................................................	  65	  
Figure	  3-­‐4.	  ......................................................................................................................................................................................................	  66	  
Figure	  3-­‐5	  .......................................................................................................................................................................................................	  67	  
Figure	  4-­‐1	  .......................................................................................................................................................................................................	  76	  
Figure	  4-­‐2	  .......................................................................................................................................................................................................	  78	  
Figure	  4-­‐3	  .......................................................................................................................................................................................................	  79	  
Figure	  4-­‐4	  .......................................................................................................................................................................................................	  80	  
Figure	  4-­‐5	  .......................................................................................................................................................................................................	  80	  
Figure	  5-­‐1	  .......................................................................................................................................................................................................	  90	  
Figure	  5-­‐2	  .......................................................................................................................................................................................................	  93	  
Figure	  5-­‐3	  .......................................................................................................................................................................................................	  95	  
  
 12 
List of Tables 
Table	  1-­‐1	  .........................................................................................................................................................................................................	  22	  
Table	  1-­‐2	  .........................................................................................................................................................................................................	  24	  
Table	  2-­‐1	  .........................................................................................................................................................................................................	  41	  
Table	  5-­‐1	  .........................................................................................................................................................................................................	  93	  
 
  
A New Non-Invasively Adjustable Glaucoma Drainage Device	   13 
 
 : Introduction Chapter 1
  
 14 
1.1 Motivation 
Glaucoma is one of the leading causes of blindness in the world1, 2. It is frequently associated 
with an elevation of the intraocular pressure (IOP), resulting from an increased resistance to 
aqueous humor outflow. The increased IOP leads to progressive and permanent damage of the 
optic nerve and, if left untreated, results eventually in vision loss3. In most of the cases the 
treatment consists in giving medications that lower IOP. When pharmacological treatments 
fail, incisional surgery developed to create alternative outflow paths to aqueous humor is 
indicated. Filtering surgery aims at increasing the aqueous humor outflow, either directly (i.e., 
trabeculectomy or deep sclerectomy) or through the use of draining implants. Since the 
inception of aqueous shunts (glaucoma drainage devices, tube implants, tube shunts), their use 
has increased and these implants are now considered by many to be the first-line surgical 
intervention for many types of glaucoma4. Nonetheless, all filtering surgery methods, 
including or not pose of drainage tubes, exhibit post-surgical complications, the rate being 
around 25%5. Post-surgical complications can often lead to surgical failures, a significant part 
of which being attributed to the lack of proper intraocular pressure control over time. This 
clearly underlines the need for a new generation of drainage implants that could provide a 
better control of the intraocular pressure (IOP). 
1.2 Glaucoma and Aqueous Humor  
Intraocular pressure plays a crucial role in the onset and severity of glaucoma. Even if the 
causes of glaucoma are not yet well understood, elevation of the IOP is one of the main 
clinical parameters governing the genesis and progression of the disease. IOP refers to the 
pressure of the aqueous humor (AH), the liquid circulating in the anterior segment of the 
eyeball. AH is produced at a relatively stable rate by the ciliary body (2 to 3 µl/minute)6 and 
exits the eyeball after passing through different structures such as the trabecular meshwork, 
the Schlemm’s canal and the collector channels (Fig. 1-1). The rate of aqueous humor 
production and outflow resistance defines the IOP level over time. For subjects without 
glaucoma, normal IOP values are in the range between 10 and 21 mmHg.   
There are several strategies available for the ophthalmologist to lower IOP, depending on the 
type of glaucoma (geometry, function, disease): a) act on the ciliary body and reduce the rate 
of production of AH, b) enhance the outflow facility of AH by changing the properties of the 
draining tissues or c) create an artificial pathway of reduced resistance to AH outflow. 
Medications are targeting the first two strategies, while surgery addresses the last one. The 
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fluidics involved in the eye are not well understood and even if some studies have described 
the behavior of AH flow in the anterior segment in 2D or 3D, little information is found in the 
literature for flow characteristics following a filtering procedure.  
 
Figure 1-1: : Horizontal slice of anterior chamber passing through the middle of the lens. (left) CA: anterior chamber, Scl: sclera, Cr.: lens, 
Cor: cornea, Ccil: ciliary body, Ir.: iris. (right) aqueous humor route from the ciliary body to and through Schlemm’s canal. (images 
courtesy of Dr. Roy) 
1.3 Filtering surgery 
1.3.1 Trabeculectomy  
At present, several glaucoma-filtering techniques are practiced clinically and most of them 
have demonstrated their efficacy5, 7-10. Trabeculectomy is the procedure of choice in glaucoma 
surgery11 (Fig. 1-2). This technique, developed in the late 60s by Cairns12, shows a fairly good 
success rate especially when combined with antifibrotic agents such as 5-fluorouracil or 
mitomycin-C13. However, even if trabeculectomy became a standard procedure in glaucoma 
management14, it often leads to post-operative complications. Durable hypotony, maculopathy, 
bleb infections, flat anterior chamber, choroidal detachment, and the lack of predictability in 
the long-term IOP control, are some of the common serious postoperative complications15. 
These complications may result in surgical failure and, in some cases, may lead to irreversible 
damages.  
 16 
 
Figure 1-2: Schematic representation of the trabeculectomy procedure and AH flowing through the new openings 
(https://doctree.in/knowledgebranch/trabeculectomy). 
1.3.2 Deep sclerectomy 
In order to avoid the drawbacks associated with penetrating filtering surgeries (e.g. 
trabeculectomy) and to improve the predictability of the IOP lowering action, various types of 
non-penetrating filtering surgeries have been proposed. There are various advantages of the 
non-penetrating surgery compared to penetrating techniques. Non-invasive procedures 
increase the predictability of the IOP lowering action and reduce the incidence of 
complications related to penetrating methods. Fyodorov and Kozlov first described the non-
penetrating deep sclerectomy in 199016, 17. This method consists in removing the main 
resistance to AH outflow by peeling both the Schlemm’s canal trabecular endothelium and the 
juxtacanalicular trabeculum (Fig. 1-3). This creates a thin membrane at the level of the 
anterior trabeculum that prevents excessive filtration of AH. In addition, the creation of an 
intrascleral filtering space, decreases the need for a subconjunctival filtering bleb, allowing 
the redirection of part of the AH into the subchoroidal space.  
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Figure 1-3: Schematic representation of a non-penetrating deep sclerectomy (image courtesy of Dr. Mermoud). 
The main advantage of deep sclerectomy resides in the absence of perforation of the anterior 
chamber, which allows a progressive decrease of the IOP. In some cases, collagen implants 
are also used to maintain the space under the scleral flap and prevent a collapse of the space. 
However, even if this technique is efficient in reducing the occurrence of complications 
related to filtering surgery, the surgical skills required and the level of knowledge of the 
anterior segment anatomy have limited the adoption of the technique to a rather restricted 
number of surgeons.  
1.4 Glaucoma Drainage Devices 
In order to prevent or decrease the rate of complications in filtering surgery or simply to 
provide other means of drainage when trabeculectomies have failed, various types of 
glaucoma drainage devices (GDD) have been designed and implemented during the last 
decades.  
1.4.1 History 
The idea of creating a hole and to maintain it to treat patients with painful absolute glaucoma 
came from Rollet and Moreau in 1907 when they decided to implant a horse-hair thread 
connecting the anterior chamber to the subconjunctival space near the limbus. Later, in 1969, 
Molteno first hypothesized and confirmed that ﬁltration failure was primarily attributable to 
subconjunctival ﬁbrosis, with ﬁstula closure occurring as a secondary event. Realizing that 
 18 
simple anterior GDDs would have little impact on this process, Molteno launched the concept 
of tube and plate GDDs, in which aqueous ﬂuid is shunted to a plate device designed to 
maintain patency of a subconjunctival filtration reservoir in the face of continuing 
subconjunctival fibrosis.  
Since the introduction of the first glaucoma drainage device (GDD) by Molteno in 196918, 
little progress has been made in developing new GDD devices with improved and distinctly 
different features. The design of these implants remained rather similar to the initial concept 
presented by Molteno; a long tube inserted into the anterior chamber, connected to an external 
endplate draining the aqueous humor under a filtering bleb. The mechanism of such an 
implant is relatively simple: the excess of aqueous humor is drained out through the lumen of 
the tube to reach the episcleral endplate located in the equatorial region of the eyeball. In this 
area the formation of a fibrous capsule creates a reservoir where the aqueous humor is 
collected. Some studies have also shown that the size of the endplate would play a role in the 
efficacy of the aqueous shunt. The dimension of the plate could be a determining factor to 
ascertain the final IOP19. Following that principle Molteno has introduced, in 1981, an 
implant with a double plate enhancing the success rate of the filtering-surgery (success 
[survival] defined as 6 mmHg < or = final intraocular pressure [IOP] < or = 21 mmHg 
without additional glaucoma surgery or devastating complication)20. Later, in 1992, Georges 
Baerveldt introduced a non-valved silicone tube attached to a large barium-impregnated 
silicone plate with different surface areas21 (150, 250, 350 or 500 mm2, Fig. 1-4).  
 
Figure 1-4: a) Baerveldt glaucoma drainage implants are shown in three sizes with surface areas of 250, 350, and 425 mm2 (left to right)22 
and b) Schematic representation of the placement of a Baerveldt pars-plana. 
Molteno and Baerveldt devices do not offer resistance to the outflow of AH and post-
operative complications such as hypotony and flat anterior chamber became a regular 
phenomenon. In that prospect and to minimize the problems related to early post-operative 
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complications, new non-adjustable valved implants appeared. Theodore Krupin was the first 
to introduce in 1976 the Krupin® valve. This implant has a slit valve that is designed to be 
pressure-sensitive and unidirectional. In theory, the valve should open only when IOP reaches 
11 mmHg23. Later, in 1993, Marteen Ahmed introduced the Ahmed® glaucoma valve (New 
World Medical, Rancho Cucamonga, CA), based on the principle of the Venturi effect with a 
pressure-sensitive valve that opens at IOPs ≥ 8 mmHg24.  
 
Figure 1-5: Single-plate and double-plate Molteno implants (top row). Krupin slit valve and Ahmed glaucoma valve (middle row). 350 mm2 
and 250 mm2 Baerveldt glaucoma implants (bottom row)58. 
 
The aforementioned devices still form the balk of the current GDD market (Fig. 1-5). 
However, new implants are appearing based on different approaches. This is the case of the 
Ex-Press® tube (Alcon, Fort Worth, TX, USA), a stainless steel translimbal implant that was 
originally designed to be implanted under a conjunctival flap but in this position it was 
unstable and tended to erode through the conjunctiva. It was then placed under a scleral flap 
in an analogous way to trabeculectomy procedure (Fig. 1-6). This non-valved device 
demonstrated efficacy in lowering IOP and its easiness for implantation has convinced many 
surgeons. As it is often compared to an improved trabeculectomy, the Ex-Press shunt is 
indicated for patients where normally trabeculectomy should be performed. 
 
Figure 1-6: a) The Ex-Press P-50 model made of stainless steel and b) how the Ex-Press mini glaucoma shunt works in the eye to divert 
excess aqueous humor from the anterior chamber to lower intraocular pressure (source Alcon Surgical website). 
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1.4.2 New and future drainage devices 
In this section, a short description of the newest glaucoma drainage devices is given. Most of 
these devices are still under clinical tests and results need to be published. 
The iStent 
The iStent (Glaukos, Laguna Hills, CA, USA) is a very small implant made of titanium, 
which is inserted through the filtering tissue meshwork (Fig. 1-7). The implant creates an 
opening between the anterior chamber and the Schlemm’s canal bypassing the resistive 
problem and drains the AH out into deeper tissues potentially decreasing IOP.  
 
Figure 1-7: The iStent trabecular micro-bypass (source Glaukos website). 
The Hydrus Stent 
The Hydrus Stent (Ivantis, Irvine, CA, USA) is a promising mini-drainage device that is 
currently in clinical trial (Fig 1-8). This device is a kind of “intracanalicular scaffold” made of 
nitinol. The Hydrus is placed in the Schlemm’s canal and creates a bypass through the 
trabecular meshwork increasing the outflow of AH.  
 
Figure 1-8: The Hydrus Stent (source Ivantis website). 
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The SolX gold shunt 
The SolX gold shunt (SOLX inc., Waltham, MA, USA) is a 24-carat-gold implant designed to 
increase the uveoscleral outflow from the anterior chamber into the suprachoroidal space 
through engraved channels (Fig. 1-9). 
 
Figure 1-9: The SOLX Gold Suprachoroidal Shunt (source SOLX website). 
1.4.3 GDD trend 
Since 1995 the trend of GDDs in glaucoma surgery is increasing, reaching +184% in 2004 
and in comparison, the number of trabeculectomy procedures decreased by 43%25. These data 
are showing that a growing number of glaucoma specialists are now choosing the glaucoma 
drainage tubes instead of traditional trabeculectomy as a first option in filtering surgery8. 
Moreover, this tendency is supported by the trabeculectomy versus tube study (TVT)11; five-
years results on treatment outcomes and complications where 212 patients were enrolled, 
including 107 in the tube group (e.g. the Baerveldt 350-mm2,) and 105 in the trabeculectomy 
group. The study demonstrated that the tube group had higher success rate than 
trabeculectomy combined with mitomycin C. The cumulative probability of failure during 
these 5 years of follow-up was 29.8% in the tube group and 46.9% in the trabeculectomy 
group. Additionally, the rate of reoperation for patients enrolled in the tube group was 9% and 
29% in the trabeculectomy group. These data demonstrated that glaucoma drainage devices 
have the potential to increase the success rate of glaucoma filtering surgery.  
Table 1-1 gives a summary of most common complications related to trabeculectomy, GDDs 
and the Ex-Press device, as reported in the literature. Hypotony, corneal issues and 
hypertensive phases were the most common complications.  
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Table 1-1: Summary of GDDs and filtering post-operative complications 
 
1.5 Hypotony 
Early postoperative hypotony is one of the most frequent postoperative complications when 
performing a glaucoma filtering surgery resulting sometimes to shallow anterior chamber. It 
is described as a hypotensive state of the eye, which over time, could lead to severe 
irreversible diseases such as choroidal detachment or hypotony-induced maculopathy. Early 
hypotony occurs during the first days after placement of the GDD, mainly due to an over 
filtration of the AH outflow. As a result, IOP decreases to values even lower than 5 mmHg. 
Often, in the following weeks, the lack of significant outflow resistance does not allow the 
eye to recover normal IOP levels (i.e., in the range of 10-21 mmHg) and only the formation of 
a fibrosis capsule around the filtration site can effectively raise the IOP, although the final 
IOP levels at long-term may vary considerably. 
In that prospect efforts were made to prevent hypotony. New implants were designed with 
flow restrictors or valves. While the incorporation of a valved flow restrictor should 
theoretically reduce the risk of immediate post-operative hypotony, the reported incidence 
rates of postoperative hypotony with this kind of GDDs (8-13%) indicate that the valves do 
not function in vivo as well as expected to do48, 49. Furthermore, leakages around the insertion 
Glaucoma 
procedures 
Trabeculectomy 
Glaucoma Drainage 
Devices 
Ex-Press 
Advantages Most used last decade 
 
-­‐ Best success rate than 
Trabeculectomy11, 30-32  -­‐ Less fibrosis  
Long-term efficacy9 
-­‐ Surgery similar to trabeculectomy -­‐ Less post-op visits7 -­‐ Good IOP reduction7, 26, 27 -­‐ Reduction of additional 
medication28, 29 
Complications No reproducible results 
Shallow or flat anterior 
chamber11, 37 
Early and Persistent 
hypotony47 
High failure rate11 
Choroidal effusion47 
Additional medication 
-­‐ Transient hypotony34, 35 -­‐ Shallow or flat anterior 
chamber11, 36 -­‐ Corneal edema 31 -­‐ Failure in IOP reduction24, 37, 
38 -­‐ Blockage of tube31, 36, 39 -­‐ Valve membrane adhesion40 -­‐ High rate of failure36 -­‐ Tube touches cornea41 -­‐ Additional surgical steps are 
required42 -­‐ Diplopia31, 43, 44 -­‐ Tube erosion11, 36, 45, 46 
-­‐ Iris incarceration7 -­‐ Contact implant-iris26, 33 -­‐ Early hypotony26, 27 -­‐ Conjunctival erosion29 -­‐ Tube obstruction28, 29  -­‐ Device rotation33 
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point through the sclera or the reduction of aqueous humor production may still result in early 
hypotony50.  
For implants such as the Molteno® or the Baerveldt®, which do not possess a valve, surgeons 
have developed numerous practical, yet not so elegant, solutions to prevent hypotony from 
occurring: a) an internal tube occlusion using a 4-0 or 5-0 nylon or Prolene suture through the 
lumen of the tube51, b) external tube occlusion creating a ligature around the tube with an 
absorbable or non-absorbable suture (Fig. 1-10A), c) tube obstruction with a collagen plug52 
(Fig. 1-10B) and d) a two stage procedure where the plate is first attached to the eyeball until 
formation of fibrosis and then insertion of the tube into the anterior chamber. However, the 
resistance to aqueous outflow through these tubes depends on the tightness of the suture or the 
completeness of the occlusion, which vary from surgeon to surgeon depending on the specific 
procedure. In addition, the rate of hypotony still remains at around 15-16% using either of 
these techniques50. Consequently, while these solutions may be effective in minimizing the 
occurrence of hypotony they require additional technical steps during surgery, including post-
operative management, without guaranteeing an optimal IOP control in all patients.  
 
Figure 1-10: Current methods used to prevent early post-operative hypotony. (A) Tube occlusion using a 8-0 Vicryl and a 6-0 Proline sutures. 
(B) Collagen plug inserted in the draining tube. 
1.6 Tube-cornea touch 
Nowadays most of the drainage devices are made of flexible, long and large silicone tubes (~ 
0.63 mm external diameter, see Table 1-2). The size and the elasticity of these tubes are 
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relatively problematic in filtering surgery. Corneal edema and/or corneal graft failure may 
develop as a consequence the silicone tube touching the corneal endothelial surface. Corneal 
endothelial damage can occur after tube-endothelial contact during blinking, eye movement or 
eye rubbing. This issue could be minimized by placing the tube portion of the GDD far from 
the corneal endothelium and parallel to the iris plane. Because of the relatively large tube size, 
enough space is required into the anterior chamber for the tube. Consequently, pars plana or 
ciliary sulcus placement were developed as to minimize the risk of corneal endothelium cell 
damages53. 
Tube migration is another factor of corneal damages. The plate might migrate forward as a 
result of wound healing and consequently the tube may protrude further into the anterior 
chamber. Some micro-movement may occur over time, resulting in corneal endothelial touch. 
The other reason for this complication is shallow anterior chamber, appearing after an 
overfiltration or hypotony. Due to the reduction of space in the anterior chamber, the tube 
may touch the cornea and cause damages, such as corneal decompensation. 
Table 1-2: Comparison of the most common Glaucoma Drainage Devices  
 
1.7 Hypertensive phase 
Several months after implanting a GDD, IOP often rises above 21 mmHg suggesting that the 
long-term control of the IOP is also a concern in glaucoma surgery management10. Even if the 
 Baerveldt® Molteno® Ahmed® Krupin® 
Plate area [mm2] 250 or 350 135 or 270 184 194 
Implant profile 
[mm] 0.84 1.65 1.9 2.54 
Material 
Smooth, 
pliable 
silicone with 
Barium 
Rigid 
polypropylene 
Rigid 
polypropylene 
or Silicone 
Silicone 
Tube external 
diameter [mm] 0.63 0.64 0.63 0.64 
Tube internal 
diameter [mm] 0.3 0.34 0.3 0.38 
Drainage tube Non-valved Non-valved Valved Valved 
Manufacturer 
Abbott 
Medical 
Optics 
Molteno 
Ophthalmic 
Ltd. 
New World 
Medical, Inc. 
Eagle Vision, 
Inc. 
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causes are not well understood, there are different theories that were proposed suggesting that 
bleb fibrosis was responsible for late failure. The hypertensive phase is generally described as 
an IOP greater than 21 mmHg. The highest rate of incidence involving ocular hypertony has 
been related to the Ahmed implant (40-80%)19, 37, 38. This postoperative elevated intraocular 
pressure is frequently caused by the formation of a capsular fibrosis around the implant10.  
The hypertensive phase is common to all glaucoma shunt designs and appears to depend on 
the materials and the shape or the size of the endplate 54, 55. Previous studies have 
demonstrated that silicone-made implants led to lower incidence of high postoperative IOP 
compared to the ones made of polypropylene55, 56. In addition, the location where the plate of 
the GDD is positioned and the size of the plate may also influence the scarring response and 
fibrosis formation. The degree of IOP reduction and therefore the long-term success of any 
GDD depend on the capsular thickness and the surface area of encapsulation. A thinner 
capsule and a larger surface of encapsulation leads to increased diffusion of the aqueous 
humor, thereby to lower post-operative IOP. For instance, the smaller surface of the Ahmed 
as compared to the double-plate Molteno or Baerveldt may lead to lower diffusion of AH, 
therefore to higher IOP19. Nonetheless, there is an undetermined upper limit on the size of the 
endplate beyond which it may not improve outflow. 
The AH contains some specific factors that enhance the fibrotic response, thereby influencing 
the filtration properties of the capsule and thus the level of hypertension57. It has been 
hypothesized that the high AH flow rates evidenced with the Ahmed valve, carrying larger 
amounts of factors promoting fibrosis, would tend to increase the rate of fibrosis compared to 
non-valved implants with ligatures19, 5. Hence, limiting the high AH flows in the early 
postoperative phase may have beneficiary effects for the long-term fibrotic response. 
Comparison of Glaucoma Drainage Devices 
There are numerous studies comparing the different glaucoma drainage devices currently 
available for the treatment of glaucoma. The average overall surgical success rate ranges 
between 72% and 79% among the five main drainage devices (Molteno single and double 
plate, Baerveldt, Ahmed, Krupin) with a statistically significant lower IOP after the operation5, 
58. These results demonstrate that GDDs have the potential to improve glaucoma filtering 
surgery outcome, however currently all GDDs exhibit complications due to poor flow control. 
New designs are needed to better control the flow and to improve the success of the procedure. 
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1.8 Requirements for next GDD generation 
The ideal GDD would be the one that allows for the maintenance of IOP levels within the 
physiological range for the entire postoperative period.  Because scaring tissue response, bleb 
formation and fibrosis are events influencing outflow resistance, one would ideally need a 
GDD with a variable resistance to compensate for the changes in outflow resistance occurring 
naturally and at different rates during the period following filtration surgery. The ideal 
situation for a glaucoma filtering surgery should be as follows: right after the insertion of the 
tube, its resistance to outflow should be maximal in order to keep the IOP high enough to 
prevent post-operative hypotony. Later on, the resistance should be reduced to maintain a 
proper control over the target IOP. Finally, the resistance of the GDD should be minimal, 
balancing the creation of fibrosis downstream. 
Following the scenario envisioned above and given the fact that tissue scaring and bleb 
formation varies among different patients, the ideal glaucoma shunt should be of variable and 
adjustable resistance, adaptable for each patient. In fact, the picture of a faucet in the eye 
would be the best way to explain what is expected: this faucet would regulate the IOP by 
changing the resistance to aqueous humor outflow at any time and in a non-traumatic way. 
In that prospect, the main body of work presented in this thesis shows the development and 
the testing of a new glaucoma drainage device. This implant is the first non-invasively 
adjustable glaucoma drainage device, which aims at providing a better solution to 
ophthalmologists by taking control of their patient’s IOP and thus reducing the rate of related 
complications.  
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Chapters 
The main body of the thesis contains 4 chapters, each chapter being a separate paper either 
already published (3) or submitted for publication (1) in important refereed journals in the 
fields of ophthlamology or bioengineering. 
Paper 1 
Glaucoma is often associated with an increase of the intraocular pressure (IOP), which results 
from an increase in the outflow resistance to aqueous humor outflow. Several treatments are 
proposed to reduce and stabilize the IOP, including medications, filtering surgery and 
glaucoma drainage devices (GDD). So far computational fluid dynamics (CFD) modeling of 
the eye drainage system has not yet been well studied. Therefore our goal was to provide a 3D 
CFD model of the eye based on the anatomy of a real human eye. Such a tool would serve for 
future evaluation of new glaucoma surgical techniques involving, for example, GDD. The 
model was based on stacks of microphotographs from human eye slides from which digital 
processing of the images of the eye structure and 3D reconstruction of the model were 
performed. Simulations of the distribution of pressure and flow velocity in the model of a 
healthy eye gave results comparable to physiology references. Mimicking glaucoma 
conditions led to an increase in the level of IOP and simulated IOP decreased significantly to 
lower values after a filtering procedure. Further refinements in the boundary conditions for 
the filtering procedure shall improve the accuracy of this innovative tool for modeling 
glaucoma surgery. 
Paper 2 
Previous mathematical models and CFD simulations allowed the optimization and 
development of an Adjustable Glaucoma Drainage Device. This 2nd paper is focused on the 
testing of a new experimental noninvasively adjustable glaucoma drainage device (AGDD) 
that allows for the control of its outflow resistance to modulate intraocular pressure (IOP) in a 
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customized fashion.  
Six AGDDs were directly connected to a pressure transducer and a perfusion system was 
continuously delivering a saline solution at rate of 2 µL/min. The steady-state pressure was 
measured and reported as a function of the angular position of the AGDD disk. Ex vivo 
experiments were conducted on six freshly enucleated rabbit eyes. The IOP was measured, 
and the flow rate was increased with a syringe pump to simulate elevated IOP associated with 
glaucoma. After insertion of the implant in the anterior chamber, the position of the disk was 
sequentially adjusted. 
The relation between the pressure drop and the angular position of the AGDD disk is 
nonlinear. The functional range lies between 80° and 130°, which allows for four or five 
different reproducible adjustment positions. Above 130° the implant is considered to be 
closed (no outflow), and below 80° it is considered to be open (minimum resistance to flow). 
The resistance to outflow of the experimental AGDD can be adjusted to keep IOP in the 
desired physiological range. This feature could be useful for addressing the risk of hypotony 
in the early postoperative stages and could provide a means to achieve optimal IOP under a 
wide range of postoperative conditions. 
Paper 3 
This work reports on the in vivo testing of a novel non-invasively adjustable glaucoma 
drainage device (AGDD), which features an adjustable outflow resistance and to assess the 
safety and efficiency of this implant. 
Under general anesthesia, the AGDD was implanted under a scleral flap on 7 white New-
Zealand rabbits for a duration of 4 months, in a way analogous to the Ex-PRESS® device. 
The device was set in an operationally closed position. The IOP was measured on a regular 
basis on both the operated and the control eyes using a rebound tonometer. Once a month the 
AGDD was adjusted non-invasively from its fully closed position to its fully open position 
and the resulting pressure drop was measured. The contralateral eye was not operated and 
served as control. After sacrifice the eyes were collected for histology evaluation. 
The mean preoperative IOP was 11.1 ± 2.4 mmHg. The IOP was significantly lower for the 
operated eye (6.8 ± 2 mmHg) compared to the non-operated eye (13.1 ± 1.6 mmHg) during 
the first eight days after surgery. When opening the AGDD from its fully closed to fully open 
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position, the IOP dropped significantly from 11.2 ± 2.9 mmHg down to 4.8 ± 0.9 mmHg (p < 
0.05). 
Implanting the AGDD is a safe and uncomplicated surgical procedure. The fluidic resistance 
was non-invasively adjustable during the entire post-operative period with the AGDD 
between its fully closed and fully open positions. 
Paper 4 
Paper 4 is neither related to the glaucoma drainage devices field nor to glaucoma itself. It 
represents a side project developed at the beginning of the thesis focusing on methods to 
evaluate or estimate the compliance of the eye vessels, a quantity of interest because of its 
potential implication in various retinal diseases. In specific, the goal of the study was to 
develop and validate a methodology to measure the compliance of the vascular network in the 
eye using biomechanical parameters, namely arterial pressure, intraocular pressure (IOP), and 
ocular compliance of the eyeball (OC). 
In vitro experiments were conducted on 6 freshly enucleated rabbit eyes. An inflatable 
catheter was inserted in the posterior chamber. The balloon was inflated and its volume 
changed periodically at a rate of 1–2 Hz, yielding variations in the intraocular volume; thus, 
emulating the volume pulsations of the vascular network in the eye. The IOP was measured 
continuously with a pressure transducer and the OC was calculated using the outflow facility. 
The compliance of the balloon, mimicking the compliance of the vascular network, was 
estimated indirectly from the measurements of IOP, balloon pressure, and OC. The estimated 
balloon compliance was compared to direct estimates of balloon compliance, based on the 
balloon pressure-volume curve. The in vivo part of the study included 5 white New-Zealand 
rabbits. The method to estimate the vascular compliance of the eye was tested under normal 
conditions and after administration of norepinephrine, which induced a vasoconstriction 
leading to reduction in vascular compliance. 
In vitro comparison of direct versus indirect estimates of compliance showed a difference that 
was not significant (0.075 vs. 0.077 µL/mmHg, P = 0.86). Results from the in vivo study 
indicated that norepinephrine significantly increased the arterial pulse pressure amplitude, 
while compliance of vascular network of the eye decreased from 0.18 ± 0.12 to 0.10 ± 0.08 
µL/mm Hg (P = 0.001). 
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We concluded that the eye vascular compliance can be accurately predicted using the IOP, 
arterial pressure, and OC of the eyeball. 
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2.1 Introduction 
Glaucoma is one of the leading causes of blindness in the world [1]. It generally results from a 
decrease of the aqueous humor (AH) outflow, which leads to an increase in the intraocular 
pressure (IOP) [2]. As a consequence the retina ganglion cells progressively suffer 
irreversible damages that lead to visual field reduction and eventually to blindness [3]. Many 
therapeutic options are available to reduce and control IOP to prevent glaucoma damages. 
Such therapeutic tools include the anti-glaucoma medications, the filtering surgery to remove 
the obstacle to egress of AH, which may include glaucoma drainage device (GDD) 
implantation, or the selective destruction of the ciliary body, to name a few [4], [5].  
Aqueous humor is produced in the posterior chamber at the level of the ciliary body at a rate 
of 2-3 µl/min [6]. The fluid then flows through the posterior portion of the iris and the 
anterior surface of the lens through the pupil to enter the anterior chamber. At this point two 
outflow pathways exist: the first one is the conventional pathway where the aqueous humor 
flows through the trabecular meshwork (TM), which is a latticed structure composed of three 
layers, the uveal meshwork, the corneoscleral meshwork, and the juxtacanalicular or 
cribriform meshwork. Cells embedded in a dense extracellular matrix form the latter and most 
of the resistance to the flow egress is commonly believed to lie at that level [7]. The second 
one is called the uveoscleral pathway and refers to the aqueous humor leaving the anterior 
chamber by diffusion through intercellular spaces among ciliary muscle fibers [8]. This 
pathway represents about 10% of the total aqueous humor outflow [9].  
After passing through these layers, aqueous humour enters the Schlemm’s canal (SC). This 
channel, which is located at the transitional zone between the cornea and the sclera, is linked 
to the veins at the surface of the sclera via 25-30 collecting channels (CC). The SC (oval 
shaped) has a mean diameter of about 120 µm [10] and a total circumference around 35 mm. 
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Finally AH is drained out of the eye through episcleral veins to get mixed with the 
bloodstream [11]. 
The fluid dynamics of AH in the anterior chamber and the role of the trabecular meshwork 
(TM) and CC are not fully understood. Consequently, computational simulation of AH flow 
in the anterior chamber can provide enlightening information about ocular diseases such as 
glaucoma where the outflow of AH is obstructed.  
Several models have previously reported temperature distribution and flow mechanisms in the 
anterior chamber of the eye using simulations and mathematical models [12-17]. However, 
the assumptions and simplifications made in these models may limit their accuracy. 
Furthermore, none of these models included the TM to obtain flow field inside the anterior 
chamber nor did they analyse its effects on IOP. Kumar et al. [18] were the first to report a 
flow simulation where the geometry of the TM was directly modelled. Intraocular pressure 
results were close to experimental observations and they concluded that buoyancy was the 
driving mechanism for the AH flow and TM accounted for the most resistive spot. 
Nevertheless this model was based on rabbit eyes and specific geometrical considerations 
have been made compared to a human eye.  
Based on these observations an exact model of the human eye including TM, SC and CC 
structures is welcomed to better understand the outflow drainage system and to evaluate the 
velocity streamlines and pressure contours in healthy eyes as well as in eyes undergoing 
filtering surgery.  
Thus the goal of this study was to develop a 3D model of the human eye based on a post-
mortem human eye and to establish the aqueous humor flow characteristics under 
physiological and pathological conditions such as primary open-angle glaucoma. This tool 
would serve as a base for further simulations and evaluations of different glaucoma surgeries 
such as trabeculectomy [19] or implantation of GDDs.  
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2.2 Material and Methods  
2.2.1 Histology preparation 
An enucleated human eye from eye banking (Cleveland Eye Bank, OH, USA) and not 
suitable for corneal grafting, was perfused at around 15 mmHg and fixed in a 4% 
formaldehyde solution for two hours. The globe was gradually dehydrated and embedded in 
wax. It was then cut at a thickness of 6 µm, each section being 200 µm apart from the other. 
Slides were stained with Masson’s trichrome. 
2.2.2 Image Reconstruction 
Each slide was photographed using a digital camera mounted on a microscope at a 4x 
magnification. The entire stack of images from the histological slices was used to reconstruct 
the eye structures. Great attention was given to details in the geometry of the structures such 
as the trabeculum meshwork, the Schlemm’s canal and the collector channels. The contours 
of the anatomical structures were extracted manually.  
2.2.3 3D geometry 
The different structures obtained from the stack of histology images were imported in 
Rhinoceros software (Robert McNeel & Associates, WA, USA) for processing. Every 
geometrical object corresponding to a particular eye structure (cornea, lens, iris, TM, SC, CC 
and the ciliary body) was treated separately to remove defaults generated during image 
extraction such as non-manifold edges, duplicate elements and degenerated faces. 
Missing structures such as the hyaloid membrane and the collector channels (n = 26) were 
added to the model. A volumetric mesh was created with ICEM CFD software (ANSYS Inc., 
Canonsburg, PA, USA) and exported to ANSYS CFX (ANSYS Inc., Canonsburg, PA, USA) 
for the fluid simulation. Evolution of the 3D construction is depicted in figure 2-1. 
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Figure 2-1: Evolution of the 3D human eye model reconstruction. (A) Histological slice. (B) 2D model extracted from histology. (C) Details 
of the TM and the SC with the used mesh. (D) 3D mesh of the human eye model. 
2.2.4 Governing equation 
In the present study the motion of AH is considered in the anterior and posterior chamber. 
Navier-Stokes equations for incompressible fluid flow were used to model the motion of AH 
in x, y and z directions.  
    ρ v ⋅∇v( ) = −∇p + µ∇2v + ρg     (1) 
where v is the velocity; p is the pressure; ρ is the density of the fluid; and µ is the dynamic 
viscosity; whereas g represents the gravitational acceleration.  
The Boussinesq approximation was used to represent the effect of buoyancy due to the 
temperature gradient. This approximation states that the density of liquid changes with 
temperature and negligibly with pressure. Boussinesq approximation can be given by: 
ρ = ρ0 1− β T −Tref( )⎡⎣ ⎤⎦     (2) 
where ρ0 defines the reference density; β is the volume expansion coefficient; and Tref is the 
reference temperature. Thus by combining the compact Navier-Stokes equation and 
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Boussinesq approximation (2), the resulting equation is the Navier-Stokes equation with an 
additional term for thermal change in fluid density given by equation (3).  
ρv ⋅∇v = −∇p + µ∇2v + ρ0gβ T −Tref( )    (3) 
Equation (4) describes the continuity that AH for steady and incompressible flow has to 
satisfy in the anterior chamber. 
∇⋅v = 0      (4) 
Finally, equation (5) describes the convective and diffusive transport of energy by AH where 
viscous dissipation effect has been neglected. 
ρCpv ⋅∇T = k∇2T      (5) 
where k is the thermal conductivity and Cp is the heat capacity. Values are summarized in 
Table 2-1. 
Table 2-1: Properties of AH used in the model 
Properties Value Source 
AH density, ρ 1000 kg·m-3 Water Properties 
AH viscosity, µ 0.001 kg·m-1⋅s-1 Kumar et al.18 
AH thermal conductivity, K 0.6 W·m-1⋅K-1 Kumar et al.18 
AH specific heat, Cp 4182 J·kg-1⋅K-1 Water Properties 
Volume expansion coefficient, β 0.0003 K-1 Water Properties 
Cornea anterior surface 
temperature, Ta 
35 °C Kumar et al.18 
Thermal conductivity of cornea, K 0.58 W·m-1⋅K-1 Heys et al.14 
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2.2.5 Permeability 
The permeability characterizes the ability of a porous material to diffuse fluids. This 
parameter is used to define the resistance of the outflow through the TM. Darcy’s law defines 
permeability of TM [20]: 
  α = µ
ΔP Δev       (4) 
where α being the permeability, ΔP is the pressure change, µ is the viscosity, Δe is the 
thickness of the porous domain, and v is the velocity component. 
2.2.6 Boundary conditions 
The iris, lens and cornea are modeled as stationary rigid boundaries, and no-slip boundary 
condition is imposed along these surfaces. The temperature of the iris and the lens is assumed 
to be at 37°C. The temperature at the surface of the cornea is generally considered to lie 
between 33 and 35 °C [21], and was assumed in this study to be 35°C. The temperature drop 
between the iris and the cornea provides the buoyant force mechanism to drive AH in the 
anterior chamber.  
The ciliary body was defined as the inflow region to simulate AH production at a rate of 3 
µl/min. The static pressure imposed at the collecting channels was estimated at 7 mmHg 
defining the pressure inside the episcleral veins. The trabecular meshwork was modeled as a 
porous domain with the corresponding permeability parameter fitted to obtain a suitable 
pressure change between the anterior chamber and the CC. Aqueous humor secreted by the 
ciliary body as well as the TM was assumed to be at 37°C.  
The working IOP condition to mimic the healthy model used in the different simulations was 
defined by an IOP of 13.5 mmHg while the glaucomatous case was defined with an IOP of 27 
mmHg. 
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2.2.7 Glaucoma Surgery 
A scleral flap measuring 5x5 mm2 and 300 µm thick was created in the model representing 
glaucoma surgery cases. Nine CC were added to the scleral flap where the static pressure is 
equal to the pressure of the episcleral veins as described previously.  
Trabeculectomy is a standard procedure for open-angle glaucoma patients initially described 
by Cairns [19] in the late 60’s. Briefly, in our simulation, it was modeled as a hole of 400 µm 
in diameter located in the irido-corneal angle in the anterior chamber, passing through the SC 
and the TM, running parallel to the horizontal plane of the iris. This hole creates a direct link 
between the anterior chamber of the eye and the inner space of the scleral flap to increase the 
AH outflow. 
The glaucoma drainage implant used in this model was the Ex-PRESS™ V50® (Ex-PRESS, 
Alcon Inc., Hünenberg, CH). A computer assisted design (CAD) model of the device was 
inserted in the 3D eye through the SC and the TM of the anterior chamber angle, parallel to 
the plane of the iris. 
2.3 Results 
The mesh of the anterior and posterior chamber as modeled contains 5,284,065 tetrahedral 
elements.  
The Schlemm’s canal is variable in appearance and in size and is represented by a single 
channel with a mean diameter of 140 µm (± 40 µm).  
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Figure 2-2: Contour of velocity magnitude and velocity vectors in anterior chamber with gravity in y (A streamlines, B vectors) and z (C 
streamlines, D vectors) directions, respectively. ΔT = 2°C. 
2.3.1 Aqueous Humor Velocity 
  
Figures 2-2A and 2-2B show the velocity distribution with the gravity in the y direction, 
perpendicular to the iris plane. This would correspond to the orientation of the eye for a 
patient in supine position. The AH is secreted by the ciliary body and then flows through the 
iris-lens gap where the velocity increases up to 7⋅10-2 mm s-1. After reaching the anterior 
chamber through the pupil, AH climbs towards the cornea where the velocity of the 
streamlines increases in the mid-portion up to 6⋅10-2 mm s-1. The streamlines then descend 
along the cornea curvature down to the irido-corneal angle where they could either exit 
through the TM or proceed further along the iris surface and then get mixed with the fluid 
flow entering the chamber, creating a recirculation zone. The highest velocity values (0.9 mm 
s-1) are present in the SC and through the CC.  
Figures 2-2C and 2-2D show the velocity distribution when gravity is applied in the z 
direction, parallel to the iris plane. This would be the case for a patient in a sitting position. In 
this model the warmer AH rises upward along the iris plane toward the apex of the irido-
corneal angle. There AH could leave through the TM or go along the posterior surface of the 
cornea down to the lower portion of the irido-corneal angle. Again there AH can leave via 
TM or climb along the iris surface. It gets re-mixed with AH coming from the posterior 
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chamber upon reaching the pupil area. A recirculation zone is created in the whole anterior 
chamber portion. Aqueous humor finally exits through the pores of the TM joining the SC and 
CC. High velocities data are present in the SC and the CC (0.9 mm s-1) and near the central 
portion of the iris surface (0.2 mm s-1).  
Velocities in the anterior chamber between healthy and glaucomatous simulations are similar.  
2.3.2 Permeability 
 
Figure 2-3: Contour of pressure in a healthy (A) and a glaucomatous (B) eye model with respective details of the trabecular meshwork and 
Schlemm’s canal. 
Aqueous flow modeling showed the pressure distribution in healthy and glaucoma simulation 
in the posterior and the anterior chambers, the trabecular meshwork, the SC and the CC 
(Figure 2-3A and 2-3B). The resistance of the TM to AH outflow determines the pressure 
drop between the anterior chamber and the episcleral veins. Several values of TM 
permeability were tested to define the IOP (Figure 2-4). Experimentations demonstrate that 
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the pressure drop in the anterior chamber is exponentially correlated to the permeability of the 
TM. 
 
Figure 2-4: Graph representing the pressure drop (IOP – CC pressure) in function of the trabecular meshwork permeability (log – log plot). 
In this model the TM was set to 1.5⋅10-15 m2 and 5⋅10-16 m2 for normal and glaucoma 
simulations, respectively, in order to achieve an IOP of 13.5 mmHg for normal and 27 mmHg 
for glaucoma. Aqueous humor pressure remains constant in the anterior chamber from the 
ciliary body to the TM, while a pressure gradient through the TM is generated down to the 
episcleral vein’s pressure. 
2.3.3 Wall shear stress 
Wall shear stress (WSS) in SC and through CC is represented in figure 2-5A & 2-5B. 
Magnitude of WSS was found to be higher at the proximal opening of the CC with a value of 
0.012 Pa. In this case, WSS in SC and CC is not influenced by the orientation of the eye. 
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Figure 2-5: Wall shear stress in Schlemm’s canal and collector channels for gravity in y direction (A) and z direction (B). 
On the other hand, the shear stress contours of the iris (figure 2-6) and the corneal surfaces 
(figure 2-7) demonstrate a difference between the vertical and the horizontal position of the 
eye. Clearly both surfaces are subjected to higher shear stresses in the vertical orientation. In 
this orientation wall shear stress is maximal in the inner periphery of the iris, whereas the 
peak is reached on the mid-periphery of the cornea in the horizontal position. Shear stresses in 
the vertical orientation show maximal values on half of the iris and on the cornea along a 
horizontal band. For instance, on the corneal surface in respect with the vertical orientation of 
the eye, WSS is equal to 6.5⋅10-4 Pa further maximal value while WSS is 2.8⋅10-4 Pa on the 
horizontal reference plane. 
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Figure 2-6: Shear stress in iris surface with gravity in y direction (A), z direction (B), and in presence of Ex-PRESS V50™ for y direction 
(C) and z direction (D). 
 
Figure 2-7: Shear stress in corneal surface with gravity in y direction (A) and z direction (B). 
2.3.4 Effect of glaucoma surgery 
The velocity contours of the flow passing through the device and the hole made by the 
trabeculectomy are depicted (figure 2-8 & 2-9). Velocities are higher for the model involving 
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the drainage device (5·10-3 m s-1) due to its smaller diameter and to the presence of a resistor 
shaft. In this model most of the flow goes through the transverse orifice.  
The results for the IOP after glaucoma surgery are the following: in trabeculectomy, the IOP 
is equal to 7.1 mmHg while when using the ExPRESS™, IOP is 8 mmHg. 
Finally, the glaucoma surgery has no effect on the shear stress of the iris surface compared to 
a normal case (figure 2-6C and 2-6D).  
 
Figure 2-8: Contour of velocity magnitude and velocity vectors in anterior chamber in presence of a Trabeculectomy. ΔT = 2°C 
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Figure 2-9: Contour of velocity magnitude and velocity vectors in anterior chamber in presence of an Ex-PRESS V50™ device. ΔT = 2°C. 
2.4 Discussion 
In this study we were interested in understanding the aqueous humor flow both in healthy 
eyes and in eyes undergoing glaucoma surgery. To achieve this goal, we have constructed a 
3D model based on images from histology slides of a human eye. Dynamic characteristics in 
respect with velocity and pressure gradient along several drops of resistance have been 
depicted.  
Schlemm’s canal and TM contours were extracted from histology images. These structures 
are the most significant parts defining the AH flow resistance. Consequently special attention 
was given to their 3D reconstruction. Results of SC thickness were compared to those found 
by Irshad et al. [10], where the SC diameter was measured using Ultrasound Biomicroscopy 
in vivo. The average diameter values reported by Irshad and colleagues (121 ± 45 µm) were 
lower than our results. Difference in results could possibly be due to disparities between in 
vivo and in vitro preparations.  
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The importance of buoyancy as the driving mechanism for AH flows has already been 
discussed previously [18]. Accordingly, we may consider that the orientation of the eye and 
the difference of temperature across the anterior chamber are the main driving mechanisms of 
AH in this region. In this study we have assumed a horizontal and a vertical upward-facing 
position of the human eye where the gravity direction is either perpendicular or parallel to the 
iris surface and the flow field is axi-symmetric. Under these conditions, the maximal velocity 
magnitude in the horizontal position is of the same order of magnitude as the maximum 
velocity found by Karampatzakis and Samaras [22] (1.7 × 10-5 m s-1) for a 3D model of the 
eye. In the vertical position, the maximum velocity result found in this study is of the same 
order of magnitude and lies between the maximum velocities calculated by Heys and Barocas 
[14] (0.7 × 10-3 m s-1) for a 3D model of the eye, Ooi and Ng [23] (1.03 × 10-4 m s-1) for a 2D 
model of the eye and Karampatzakis and Samaras [22] (3.36 × 10-4 m s-1). It is worth noting 
that in the Heys and Barocas and Ooi and Ng studies, the temperature of the corneal surface 
was kept constant at 34°C, whereas in the current study the temperature is higher, resulting in 
a smaller temperature gradient and consequently a lower velocity value.  
In this study we have considered the TM as a volume with a constant determined permeability. 
Therefore it is represented by a porous structure with uniform resistance all over the filtration 
volume. However, in reality the human eye is made up of three layers with different porosity; 
the uveal meshwork, the corneoscleral meshwork and the juxtacanalicular or cribriform 
meshwork. The latter presents the highest resistance to AH egress [24]. In a previous study, 
Ethier et al. [13] described two possible structural models of the juxtacanalicular meshwork 
(JCM); a model A which represents JCM as a series of open spaces within a solid framework 
and a model B where the open channels are filled of a gel-like material. Murphy et al. [25] 
used these models to calculate the hydrodynamics properties of JCT. When using model A, 
they found the TM permeability for healthy patients ranged from 2 to 10⋅10-15 m2 while 
permeability varied between 2.9 and 3.4⋅10-16 m2 for patients suffering from open-angle 
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glaucoma. Our model is in agreement with these results. Nevertheless Murphy and colleagues 
found that the computed permeabilities from model A were much too high compared with the 
value they expected to achieve. For instance to match at best the experimental data we have a 
too large TM to build up a significant flow resistance unless it is filled with viscous material 
like in the model B. In the future, the structure of the TM and its complexity should be 
implemented in our model. Instead of having a uniform resistance represented by porous 
structures, the TM spaces and its different layers should include a gradient of porosity and it 
should be filled with a gel-like material to be consistent with the experimental data. 
2.4.1 Wall shear stress 
Wall shear stress studies are important for the investigation of endothelial cells’ functions and 
structures [26]. In this model WSS was computed for the SC and the CCs and results could 
possibly be used to determine the biomechanical forces applied to Schlemm’s canal 
endothelial cells. From that prospective, Ethier et al. [27] characterized the biomechanical 
environment of Schlemm’s canal endothelial cells by estimating the average shear stress in 
SC. In their study, Ethier et al. showed that Schlemm’s canal endothelial cells were exposed 
to a combination of shear stress and basal-to-apical pressure gradient resulting in different F-
actin architectures. Using their calculations of the average shear stress upon the SC height, 
WSS at collector channel ostium is equal to 7·10-3 Pa, which is of the same order of 
magnitude as the WSS computed in our model (1.2⋅10-2 and 9⋅10-3 Pa). Differences are 
likely due to approximations made in the size of the SC in our model, which allowed 
fluctuations in its diameter. 
The magnitude of the WSS on the iris surface is an important parameter for the prevision of 
endothelial cell detachment in Pigment Dispersion Syndrome and Pigmentary glaucoma [18, 
28]. According to Gerlach [29] and colleagues, the magnitudes required to detach such cells 
are comprised between 0.51 and 1.53 Pa. In that respect, the comparison between the vertical 
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and the horizontal orientation of the iris and the corneal surfaces in our study demonstrated 
that the WSS results are lower than the values predicted to detach the endothelial cells. So it is 
unlikely that fluid shear stress could detach pigments from the anterior iris surface in our case. 
Nevertheless the probability and location of pigments detachment on the iris surface could be 
predicted using the plot of shear stress in case of some specific disease. 
Further studies of shear stress in the eye involving different parameters could possibly be first 
tested with the present model. Results provided by the WSS simulations in this study support 
this idea. 
2.4.2 Filtering surgery 
The role of the glaucoma filtering surgery is to reduce IOP by increasing AH outflow. A 
retrospective comparison between trabeculectomy and an Ex-PRESS™ device inserted under 
a scleral flap showed the efficacy in lowering IOP for both surgeries [30]. With a follow-up of 
3 months, the reduction of IOP was similar in both techniques. However, from day 1 to month 
3 after surgery the IOP was significantly lower after trabeculectomy compared to the Ex-
PRESS™ shunt implantation. This resulted in lower rates of early postoperative hypotony 
using the Ex-PRESS™ implant. Maris et al. [30] suggested that this difference was due to the 
additional resistance to AH flow provided by the smaller lumen of the Ex-PRESS™. In our 
study, resistance to AH outflow decreased and low IOP was established in the anterior 
chamber in presence of both procedures. In case of trabeculectomy, IOP was closer to the 
pressure of episcleral veins than in presence of the Ex-PRESS™ implant. Likewise Maris and 
colleagues found that the lumen of the device played a significant role in decreasing IOP in 
the anterior chamber.  
Velocity streamlines using the Ex-PRESS™ tube demonstrated the importance of the lateral 
orifice to increase AH outflow. Results indicated that the resistor shaft inserted in the inner 
lumen is of major importance in contributing to the AH flow resistance. Such observations 
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were demonstrated by Broquet et al. [31]. In their study, they have made the same 
observations after similar simulation in ideal human eye geometry. Broquet and colleagues 
have shown that most of the resistance to AH egress through the device occurred at the level 
of the resistor shaft and most of aqueous humor flow occurred through the lateral orifice of 
the filtering device. Such simulations have supported the effectiveness of surgical 
interventions when AH flow resistance was high. 
Finally fibrosis is believed to play an important role in the success of glaucoma surgery. In 
order to have a more realistic model, it is essential to create a time-varying fibrosis model 
where the resistance of outflow is changing over time. As such the scleral flap could be filled 
with a porous media representing the fibrotic tissue. Moreover the uveoscleral pathway has 
not been taken into account in this study. Previous studies have reported that the uveoscleral 
pathway can be in the range of 0.8 up to 1.0 µl/min [32, 33]. While it does not account for an 
important part of the total AH outflow, it has been nevertheless reported that this pathway 
decreases significantly with age [32, 33]. Furthermore it was also shown that the uveoscleral 
drainage could be IOP dependent [34]. Such observations are interesting as age and pressure 
dependent changes in the uveoscleral pathway should be considered to enhance the accuracy 
of this model in the future. 
2.5 Conclusion 
We have presented a three-dimensional model of the human eye that could be used to 
investigate the pressure drop and the localization of the main resistance to aqueous egress. 
Results of such simulations representing healthy and glaucoma eyes were consistent with 
previous 2D and 3D models based on ideal geometries. The addition of a filtering procedure 
showed a real diminution of the IOP.  
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Such model could help in determining the optimal placement and design of GDDs and 
glaucoma surgical techniques. However, some refinements still need to be done to improve 
precision and efficacy such as the addition of the uveoscleral pathway, remodeling TM and 
the implementation of a time-varying subconjunctival fibrosis after filtering surgery. 
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3.1 Introduction 
Glaucoma is one of the leading causes of blindness in the world 1,2 and lowering the 
intraocular pressure (IOP) to prevent optic nerve damage is one of the solutions to control 
glaucoma progression. Medication is the primary therapy used for patients suffering from 
glaucoma. However for some patients, pharmacological solutions may be inefficient and 
surgical procedure is required 3. 
Several glaucoma-filtering techniques exist and most of them demonstrated efficacy in 
lowering IOP4-6. They all aim at decreasing the resistance to aqueous humor outflow by 
creating an additional flow pathway to the conventional ones. For several decades 
trabeculectomy 7 was one of the most frequently used surgical techniques. However, recent 
studies have shown a positive trend in the use of drainage devices in glaucoma surgery while 
the rate of trabeculectomy is decreasing 6. The increasing popularity of filtering devices can 
be attributed to the fact that IOP is reduced in a way that is associated with fewer side effects 
compared to established techniques8. 
The Ex-PRESS mini shunt is a stainless steel implant inserted under a scleral flap, and the 
operation is similar to the trabeculectomy9,10. Even if the rate of early hypotony has decreased 
using this kind of device compared to classic trabeculectomy, the rate of complications 
remained comparable11-13. This implant aims at improving the way trabeculectomy works. 
However, as for all filtering procedures, the lack of proper IOP control can lead to post-
surgical complications. Hypotony remains one of the main complications in the early steps 
post-surgery and a proper control of the IOP through the adjustment of the aqueous humor 
egress would probably help minimizing the occurrence of such post-operative complications. 
In that prospect, the ideal filtering device should consist of an adjustable resistor valve that, 
upon proper adjustment, would take into account the post-operative hypotony and allows for 
customized adjustments of the IOP. 
In this study we present the very first report of a novel adjustable glaucoma drainage device. 
Preliminary results from in vitro perfusion tests and ex vivo studies on enucleated eyes 
demonstrate that the model device is able to effectively and reproducibly control the 
resistance to aqueous humor (AH) egress. 
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3.2 Materials and Methods 
3.2.1 Adjustable glaucoma drainage device 
Figure 1 shows the adjustable glaucoma drainage device (AGDD) (Fig. 3-1A) and its external 
control unit (CU) (Fig. 3-1B), which is used to a) read the functional position of the implant 
and b) adjust its fluidic resistance. The concept of the adjustable glaucoma drainage device 
was first invented by Stergiopulos14 and later developed and patented by Bigler and 
Stergiopulos15. The AGDD is designed to drain aqueous humor with a resistance to outflow 
that can be externally regulated. The implant is inserted surgically under a scleral flap, in a 
manner similar to the Ex-PRESS shunt4. It is composed of a deformable silicone (MED-4830, 
Nusil, FL, USA) tube (outer diameter 0.3 mm, internal diameter 0.2 mm), which drains AH 
from the anterior chamber into a bleb formed in the scleral space. For a given rate of drainage, 
the IOP depends on the fluidic resistance of the tube. The implant contains a mechanism (Fig. 
3-2), which allows for a variable compression of the tube, altering its cross-sectional area 
accordingly and thus changing the fluidic resistance. The various levels of compression in the 
tube are achieved by rotating a magnetic disk around a shaft, which is eccentric to its axis of 
symmetry. The angular position of the magnetic disk defines the length of the tube that is 
compressed as well as the degree of radial compression. 
The external measurement/adjustment device, also termed as control unit (CU), is depicted in 
Figure 1B. The CU has been designed to help the physician perform two essential functions: 
a) measure the functional (angular) position of the implant, and b) perform a noninvasive 
adjustment of this functional position, in order to optimize the drainage characteristics (fluidic 
resistance) of the implant. The measurement of the angular position of the magnetic disk is 
performed with the use of a flat compass, which is situated in one of the two ends of the 
control unit. The magnetic needle is colored to indicate the “north pole” and the transparent 
cover slip or the outer rim of the compass housing contains graduations for easier reading of 
the angular position of the needle. The other extremity of the control unit contains a 
permanent magnet for performing the adjustment. To adjust the angular position of the 
implant, the operator first reads the actual angular position of the implant’s magnetic disk by 
placing the compass above of the implant (Fig. 3-3). Once the angular position is read, the 
operator flips the CU 180 degrees to bring the CU magnet in the vicinity of the implant, in 
order to couple magnetically the external magnet to the internal magnetic disk. The operator 
then drags the magnet in a clockwise or counterclockwise direction along a circular arc 
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around the implant, forcing thus the internal magnetic disk to rotate accordingly. The operator 
verifies the new angular position of the implant using the compass again. 
 
Figure 3-1: Picture of the Adjustable Glaucoma Drainage Device (A) and its Control Unit (B). 
The mechanism (Fig. 3-2) and the tube of the AGDD are encapsulated within two shells made 
of synthetic polymer (PEEK Optima, Invibio, UK). These shells are hermetically shielded to 
protect the mechanism from tissue contact and fluid entry, which could jeopardize its 
functionality over time. The aqueous humor enters the tube through the nozzle and exits at the 
backside of the implant, totally shielded from implant’s interior. To optimize the positioning 
of the device under a scleral flap, the shells and the mechanism have been designed to match 
the radius of curvature of the human eye. 
 
Figure 3-2: Synthetic image depicting the details of the mechanism of the AGDD. Under the steering effect of external magnetic fields, the 
magnetic disk of the implant turns around an eccentric axis pushing or retracting radially the external ring of the bearing ball mechanism. 
The radial motion of the external ring leads to a change of the cross-sectional area of the elastic tube, thereby modifying its fluidic resistance. 
Nozzle
Tube
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3.2.2 In vitro experimentation 
The AGDD was connected to a syringe pump (SP210iw, World Precision Instruments, FL, 
USA) pushing through the implant’s tube saline solution at a rate of 2 µL/minute. The saline 
solution would flow out of the distal end of the tube into the atmosphere. Pressure upstream 
of the implant was measured with an electronic manometer (BLPR2, World Precision 
Instrument, FL, USA). The manometer was connected to a data acquisition card (DAQPad-
6015, National Instruments, TX, USA) to give real-time pressure readings via a custom 
interface (LabView 9.0, National Instruments, TX, USA). 
The angular position of the implant was changed using the CU. The magnet’s angular position 
was adjusted from 0° to 180° (in 5° steps) and the steady-state pressure was recorded at each 
position. Three sets of data of pressure vs. angular position were obtained for each implant. 
Experiments were conducted on 6 different implants. 
3.2.3 Ex vivo experimentation 
Six freshly enucleated eyes (post-mortem time less than 4 hours) from white New Zealand 
rabbits were obtained from a local farm. The eye was hold on a brace, and the anterior 
chamber was cannulated with a 24-gauge catheter (Optiva W, Smiths Medical, Rossendale, 
UK) filled with saline solution that was delivered by a syringe pump at a rate of 20 µL/min 
during the experimentation. The catheter was inserted between the anterior plane of the iris 
and the posterior surface of the cornea. The system was connected to an electronic manometer 
and real-time pressure reading and recording were performed as for the in vitro experiment, 
after implanting the device. The angular positions of the magnetic disk were adjusted from 0 
to 180° at intervals of 5°. 
3.2.4 Surgical procedure 
The eye was maintained on the mounting unit and a 24-G canula (Optiva W, Smiths Medical, 
Rossendale, UK) was inserted in the anterior chamber. The canula was connected to a water 
column containing saline solution, so that physiological ocular rigidity was maintained 
throughout the surgery. The height of the column was set to pressurize the eye at 25 mmHg. 
A square scleral flap, 7 × 7 mm, was cut using a crescent sapphire blade down to 1 mm from 
the limbus. A 24-G needle was then used to poke the scleral wall and to enter the anterior 
chamber, creating a hole for entering the device’s nozzle into the anterior chamber. Because 
the nozzle was inserted in the space between the cornea and the anterior surface of the iris, 
care was taken not to touch either of these structures. The implant was secured using 2 single 
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Nylon 10-0 sutures, and the scleral flap was repositioned and sutured using 2 single point 
Nylon 10-0. Finally, the 24-G canula was connected to the syringe pump delivering 20 
µL/minute, which deemed necessary to maintain IOP above 21 mmHg. 
3.2.5 Outflow facility measurement 
Details of outflow facility measurement have been reported previously 16,17. Briefly, the 
anterior chamber was perfused at first with a defined flow rate (2 µL/minute). After a stable 
IOP level was reached, the flow rate was changed to a higher value until another stable IOP 
level was reached. The outflow facility (OF) was then calculated using the Goldman equation 
OF = ΔQ/ΔIOP (ΔQ = (Q2-Q1)) 
where Q1 and Q2 are successive inflow rates (µL/minute), ΔQ = Q2 – Q1 and ΔIOP = (P2 -
P1), with P1 and P2 representing IOP at Q1 and Q2, respectively (mmHg). 
3.2.6 Statistics 
The results were expressed as the mean and standard deviation (mean ± SD). The paired 
Student’s t-test was used to assess significant differences in angular position adjustments on 
the results. P < 0.05 was considered statistically significant. 
 
Figure 3-3: Synthetic image showing the positioning of the implant within the scleral flap and the compass of the CU, which is used to read 
out the angular orientation of the implant’s magnetic disk. The operator may adjust the angular position of the implant using the CU magnet. 
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3.3 Results 
3.3.1 In vitro experimentation 
The relationship between the pressure drop and the adjustment is non-linear (Fig. 3-4). From 
position 0° to 80° the resistance of the tube is equal or close to 0 (p = 0.2) meaning the AGDD 
configuration is fully open. From position 120° and higher the pressure drop is high (> 30 
mmHg) and adjustments become less accurate. 
Significantly different pressure drops may be achieved every 10° (Δθ) from 90° to 130° (p < 
0.05). Under 10° steps differences in pressure are no more statistically significant. This means 
that the angular resolution of the device is approximately 10°. 
The resistance of the AGDD to aqueous outflow when totally open (position 0°) is equal to 
0.05 mmHg·minute/µL. 
 
Figure 3-4: In vitro measurements of the pressure drop vs. the angular position of the magnetic disk. The operational range is comprised 
between 80° and 130°. Values are given as average ± standard deviations (n = 6). The operational range of the device is defined as the 
angular range between its fully closed and fully open position. The fitted curve corresponds to a power law: f(x) = a*xb+c, where a = 
4.81*10−14, b = 7.056 and c = −0.15. R2 = 0.99. 
3.3.2 Ex vivo experimentation 
The outflow facility before surgery was 0.33 ± 0.09 µL/mmHg/minute and 1.27 ± 0.19 after 
implantation (p < 0.05). To maintain high pressure in the eye, the flow rate was increased to 
20 µL/minute resulting in an IOP of 23 ± 2.5 mmHg when the implant was in a fully closed 
position. 
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The angular position of the AGDD was adjusted in steps of 5 degrees and the IOP at the new 
steady state was recorded (Fig. 3-5). The IOP range from the fully closed to fully open 
position ranged from 23 ± 2.5 to 3.7 ± 0.7 mmHg (p < 0.05). 
IOP vs angular position curves from in vitro and ex vivo measurements (Fig. 3-4 and 3-5) 
were fit with an empirical power law (y = a*xb+c). The corresponding values were: b = 7.056 
± 0.706 for in vitro and b = 7.004 ± 1.297 for the ex vivo experimentation, demonstrating, as 
expected, an identical exponent in the power law for the in vitro and ex vivo experiments. 
 
Figure 3-5: Ex vivo measurements of the pressure drop as function of the angular position of the magnetic disk. The implant was surgically 
placed in its intended anatomical position under a scleral flap in enucleated rabbit eyes. Values are given as average ± standard deviations (n 
= 6). The operational range of the device is defined as the angular range between its fully closed and fully open position. The fitted curve 
corresponds to a power law: f(x) = a*xb+c, where a = 2.26*10-14, b = 7.004 and c = 4.739. R2 = 0.98. 
3.4 Discussion 
In this study, we have tested a new experimental adjustable glaucoma drainage device, which 
allows for a non-invasive and non-traumatic adjustment of the fluidic resistance of the shunt, 
thereby offering a customized control of intraocular pressure. The present in vitro and ex vivo 
experiments are the first steps to validate the fluidic characteristics and performance of this 
new implant. Results show that the drainage device described in this study can be adjusted by 
varying the angular position of the disk using an external magnet, thus modifying the cross-
section area of the draining tube and changing its fluidic resistance. The resistance may vary 
from infinite (fully closed position) to a minimal value (fully open position), allowing the user 
to select over a wide range of IOPs. 
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The working range for the angular position of the implant is situated between 80° and 130°. 
Angular positions outside of this range correspond to fully open (θ ≤ 80°) or fully closed 
configurations (θ ≥ 130°). Within this working range and given the fact that the angular 
resolution is in the order of 10°, there are effectively 4-5 distinctly different positions that the 
user can select with good confidence in order to alter the resistance. This means that there is 
not only a binary system (open/closed) configuration, but there is also the possibility to 
selectively set the resistance of the implant, and thus adjust IOP in accordance to the different 
patient needs. 
The pressure drop across the implant for a given flowrate is non-linearly related to the angular 
position of the implant’s disk. The angular position of the magnetic disk of the implant 
defines the degree of compression of the elastic tube, which defines the internal cross-
sectional area of the tube and thus its fluidic resistance. According to Poiseuille’s law, the 
hydraulic resistance (RH) to flow is inversely proportional to the radius (r) of the tube to the 
power 4 (RH ∝ (1/r4)). Thus when the hydraulic inner radius of the tube becomes smaller 
(due to compression by the magnetic disk), the resistance increases by the power of 4, e.g. a 
reduction by half of the diameter leads to a 16 times increase of the resistance. For the 
particular implant design, the degree of compression is non-uniform along the tube and it is 
nonlinearly dependent of the angular position θ. An empirical fit of the pressure drop vs. 
angular position of the magnetic disk shows that pressure drop is proportional to the angle of 
adjustment to the seventh power. The resistance has therefore a very strong non-linear 
dependence on the angular position of the disk. The non-linearity of the system might be a 
limitation, as it reduces the number of adjustment points, making the system very sensitive to 
the angular position. An ideal system would exhibit a linear adjustment of the resistance as 
function of the angle of the disk. In that case, the angular working range would be greater and 
the angular precision on the adjustment would be less stringent. 
During the ex-vivo experiments, eyes were artificially maintained at a pressure above 21 
mmHg to mimic glaucoma conditions. High flow rates were used to stabilize IOP at such high 
level. This is mainly due to higher outflow facility of cadaveric eyes and to leakages 
occurring all around the insertion point of the implant’s nozzle. The tests on the enucleated 
eyes demonstrated the efficacy and reproducibility of the AGDD to decrease IOP at various 
levels, depending on its angular position. Minimal pressures reached after total opening of the 
AGDD were slightly higher than zero due to high flow rates used in these experiments. 
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Based on these laboratory investigations, we plan to test the AGDD on an experimental 
animal model to confirm these initial results and to further evaluate the biocompatibility, the 
controllability and the efficacy of such device implanted in a living eye. The ultimate goal 
will be to conduct a clinical trial on patients suffering from medically uncontrolled glaucoma 
requiring a filtering procedure. In that prospect, the fine-tuning of the AGDD would be 
performed post-operatively according to the IOP measurements. For instance, if the IOP were 
too high (i.e., above 20 mmHg), the clinician would set the position of the magnetic disk of 
the AGDD in a new orientation to decrease its fluidic resistance and thus lower IOP. 
Conversely if the IOP is too low (i.e., below 5 mmHg, for instance), the clinician could 
modify the orientation of the disk to increase the resistance to aqueous egress, resulting in an 
increase of the IOP. In the early post-operative period, and when hypotony is present, the 
operator could set the AGDD in a fully closed position that would help increasing the IOP, 
thus contributing to minimize the problem of persistent post-operative hypotony and 
potentially decreasing the complications related to hypotony. The above envisioned scenario 
is speculative and needs to be verified through in vivo experiments in animals and in 
appropriately designed clinical studies. 
In conclusion, this study demonstrates that the resistance to AH egress can be selectively 
changed with an adjustable glaucoma drainage device. This device provides various outflow 
resistances, which can be adjusted to bring IOP to clinically acceptable values. The 
adjustment can be performed simply and non-invasively using an external control unit. The in 
vitro results presented here need to be confirmed in vivo on the animal and on the human. 
Specifically, critical aspects, which cannot be studied in vitro, such as the biocompatibility, 
complications related to filtration, overall safety and the efficacy of the AGDD, will be 
investigated on an animal model before proceeding to a pilot human trial. The simplicity of 
the device, the relative ease with which resistance is adjusted over a wide range and the 
standard way of implanting allow us to hypothesize that this first ever adjustable glaucoma 
drainage device may prove to be a valuable tool in the surgical treatment of glaucoma. 
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4.1 Introduction 
Glaucoma is a leading cause of blindness affecting millions patients worldwide1, 2. Decreasing 
the intraocular pressure (IOP) is one of the most important requirements to efficiently control 
the progression of glaucoma3. The number of valuable options in glaucoma filtering surgery 
has increased over the last decade4, 5. Trabeculectomy and the use of implantable drainage 
devices or stents are parts of the armamentarium available nowadays in modern glaucoma 
filtering procedures. Glaucoma drainage implants become increasingly popular because they 
may offer better IOP control overtime, reducing the number of post-operative complications 6, 
7. Still, predicting postoperative IOP and maintaining it at optimal levels remains a key 
problem. For instance, the risk of early post-operative complications, such as hypotony, is 
always present. Hypotony could entrain complications requiring further surgeries8, 9. In that 
respect, the possibility to control of the fluidic resistance of an implanted drainage device 
during the post-operative follow-up would have been very helpful in maintaining IOP always 
at optimal levels, thereby potentially avoiding a number of complications related to poor 
pressure control. 
Recently, a new experimental non-invasively adjustable glaucoma drainage device (AGDD) 
has been developed10. In vitro results demonstrated that the fluidic resistance of the device 
can be adjusted to consequently regulate the IOP. In order to assess the safety and the 
efficiency of the novel device, this study reports the first in vivo testing of this AGDD.  
4.2 Methods and Materials  
The principle of the AGDD system was first described by Stergiopulos 11, further developed 
and patented by Bigler and Stergiopulos 12 and described in details by Villamarin et al. 10. 
Briefly, the system comprises of a) the AGDD implant and b) the external 
measurement/adjustment device, hereafter called the control unit (CU) (Fig. 4-1). The AGDD 
contains a simple mechanism, which allows for a selective compression of an incorporated 
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drainage tube, thereby adjusting its fluidic resistance. This is achieved using the combination 
of an eccentrically placed magnetic disk (that is placed on ball bearings facilitating its 
rotation) and a ring compressing the silicone tube; the angle of rotation thus determines the 
amount of compression of the drainage tube, and therefore its fluidic resistance. The magnetic 
disk is rotated using the CU, which contains a magnet at one end and a compass on the other 
end. When placed on top of the implanted AGDD, the compass indicates the actual rotational 
position of the magnetic disk. The magnet is used to rotate the magnetic disk, by 
appropriately dragging the magnet along the periphery of the implant in the clockwise or 
counterclockwise direction. Both the reading (compass) and the adjustment (magnet) of the 
rotational position of the implant is done non-invasively and without even touching the eye 
(Fig. 4-1).  
 
Figure 4-1: Picture of the AGDD (A) and the Control Unit (B) used for the measurement and the adjustment of the outflow resistance. 
4.2.1 In vivo experiment 
The study was carried out on 7 white New-Zealand rabbits for duration of 4 months. General 
anesthesia was performed using a mixture of 3 mg/kg (body mass) xylazine and 35 mg/kg 
ketamine intramuscular injection. Under general anesthesia, the AGDD was implanted in a 
way analogous to the Ex-PRESS® device13. In short, a scleral flap of 7x7 mm (width x long) 
was dissected and the nozzle was inserted in the anterior chamber between the cornea and the 
anterior surface of the iris taking care not to touch either of these structures (Fig. 4-2). The 
AGDD was implanted in a functionally closed position and left in that position during the 
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initial postoperative period (1 month). The end portion of the tube was placed freely under the 
conjunctiva and aqueous humor was drained in the subconjunctival space. 
During the first postoperative week, IOP was measured daily on both the operated and the 
control eyes using a rebound tonometer (iCARE Tonovet, iCare, Finland). In the following 
weeks, such measurement was performed once a week. Results were reported and compared 
for statistics. Before each measurement, rabbits were placed in a bunny snuggle (Colonial 
Medical Supply, NH, US) and relaxed for 5 minutes. All measurements were performed at the 
end of the morning (10 a.m. to 12 a.m.). 
Once a month the AGDD was adjusted non-invasively with the CU from its fully closed 
position to its fully open position and the resulting pressure drop was measured. Hypotony 
was defined as an IOP equal or lower than 6 mmHg (IOP ≤ 6 mmHg). The contralateral eye 
was not operated and served as control. At the end of the study the animals were sacrificed 
and the eyes were enucleated to perform histology in order to assess the biocompatibility of 
the AGDD. 
All experiments conformed to the ARVO Statement for the Use of Animals in Ophthalmic 
and Vision Research, and were reviewed and approved by the institutional committee for 
animal studies in Lausanne, Switzerland. 
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Figure 4-2: Picture of a rabbit eye where the AGDD was placed under a scleral flap with its nozzle inserted in the anterior chamber. 
4.2.2 Histology 
The enucleated eyes were formalin-fixed, macroscopically processed, and dehydrated through 
graded alcohol followed by paraffin inclusion. Five µm sections were cut and the following 
stains performed: Hematoxylin-Eosin, and Prussian Blue. 
4.2.3 Statistics 
The results were expressed as the mean and SD. The paired Student’s t-test was used to assess 
significant differences and effects of the AGDD on the results. P < 0.05 was considered 
statistically significant. 
4.3 Results  
The mean preoperative IOP was 11.1 ± 2.4 mmHg. The evolution of IOP during the entire 
post-operative period for the animals is shown in Figure 3. For the 7 rabbits, hypotony was 
present in the operated eyes during the first 3 days after implantation (mean IOP was 6 ± 1.4 
mmHg) and the difference with the control (non-operated) eyes was significant (p < 0.05). 
Eight days after surgery, hypotony was no longer present (mean IOP 11.3 ± 0.8 mmHg) and 
the difference in IOP between control and operated eyes was no longer significant (p = 0.12) 
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(Fig. 4-3). In all rabbits, the IOP dropped significantly from 11.2 ± 2.9 mmHg down to 4.8 ± 
0.9 mmHg (p < 0.05) when the AGDD was opened from its fully closed (maximum outflow 
resistance) to fully opened (minimum outflow resistance) position (Fig. 4-4). The range of 
IOP from the closed position to the open position of the implant corresponds to [closed min= 
7 mmHg, max=17 mmHg] and [open min=4 mmHg, max 7 mmHg]. The pressure drop was 
significant for all rabbits (p < 0.05) and it was reproducible from one rabbit to the other. 
 
Figure 4-3: Plot of the IOP over time. Measurements were done every week with an iCARE TonoVet. Post-operatively the difference 
between the operated and the control eyes was significant from day 1 to day 8 (*). Transient hypotony was present in the operated eyes 
during the first 3 days after implantation. 
Microscopic examination of tissues surrounding the AGDD showed a cavity covered by a 
layer flattened macrophages surrounded by partially reorganized dense connective tissue. In 
some areas, aggregates of lymphocytes as well scarce eosinophils could be identified. The 
chronic inflammatory infiltrate was minimal and mild in most of the cases (Fig. 4-5). A 
granulomatous foreign body type reaction was observed around the suture material. 
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Figure 4-4: Plot of the IOP over time and the AGDD in its functionally closed position. Once a month, the AGDD was fully opened and the 
resulting pressure was measured (red square symbol). The arrows help visualizing the magnitude of the pressure drop when the device was 
adjusted from its fully closed to its fully opened position. 
4.4 Discussion 
The advantage of the novel glaucoma drainage device resides in the possibility to adjust, non-
invasively, its fluidic resistance to the aqueous humor drainage. In that prospect, the goal of 
this study was to demonstrate the safety, efficacy, ease of use and biocompatibility of the 
AGDD in an animal model.  
 
Figure 4-5: Histopathological analysis demonstrated a cavity lined by flattened cells surrounded by few lymphocytes.  Circumscribed post 
surgical cicatricial remodeling can be observed inferior to the cavity in the dense connective tissue of the sclera. Original magnification: x 
63; stain: Hematoxylin-Eosin. 
Although rabbits are standard animal models commonly used in ophthalmology research14, 
the size of the rabbit eye is significantly smaller than humans. However, the anatomical 
structures are comparable, providing a useful surgical model for ophthalmic investigations15. 
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The rabbits used in this study did not suffer from glaucoma. It is rather difficult to induce 
glaucoma on rabbit eyes and to maintain an elevated IOP over time. Several techniques such 
as injection of microbeads into the anterior chamber16 or occlusion of episcleral vessels17, 18 
can be effective but do not work for long-term follow-ups. In addition, these techniques were 
tried on rodents such as mice or rats that have too small eyes for the implantation of the 
AGDD. Therefore, the capability in reducing elevated IOP to normal range (as it would be the 
case for patients suffering from glaucoma) could not be tested in this study. However, the 
ability of the AGDD to reduce pressure levels (from normal to low pressures) has been clearly 
demonstrated. Because the implant operates on altering the fluidic resistance, one could 
imagine that in presence of glaucomatous eyes, the IOP could be reduced to pressures down 
to physiological range. Results show that the implant has efficiently decreased the IOP once it 
was in its functionally open position. These results demonstrate that over time the AGDD can 
be adjusted non-invasively and consequently the IOP can be adjusted accordingly. When the 
implant was re-adjusted from the fully open to its fully closed position, the following day, the 
IOP resumed its initial level (Fig. 4-4). These observations are very encouraging, 
demonstrating the efficacy of the implant to change the IOP and to customize the intraocular 
pressure specifically thinking to the needs of the patients. Nonetheless, further investigations 
are needed to clinically address elevated IOP in glaucoma patients.  
The surgical method to implant the AGDD is analogous to the Ex-PRESS tube, which is 
comparable to the trabeculectomy technique19. Nevertheless, some minor changes were 
necessary to correctly implant the AGDD. For instance, the size of the scleral flap was 
substantially larger (7mm x 7mm) to correctly fit the size of the AGDD.  
Results show that after a week (8 days, Fig. 4-3) the difference in IOP between control and 
operated eyes was no longer significant. For the eyes implanted with the AGDD, the IOP 
went back to preoperative level after only a few days following surgery and the hypotony was 
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thus minimized (< 4 days). This short recovery time after a filtering procedure results from 
the fact that the AGDD was inserted in its functional closed position thus limiting outflow to 
the leakages around the nozzle and allowing the eye to resume the initial IOP level. However, 
one should consider the increase in resistance resulting from the postoperative scarring of the 
rabbit eye 20. In humans, scarring would certainly have a different time profile and the control 
of optimal IOP pressure would be achieved by tuning the fluidic resistance of the implant 
following the fibrosis of surrounding tissue and the overall scarring response. The 4 months 
follow-up may be to short to fully evaluate the mid- to long-term safety and efficacy profile of 
this AGDD. This is the main limitation of this study. Further clinical evaluations are planned 
to address these issues. 
The use of this AGDD as a modular flow resistance is most efficient in the early stages after 
implantation. Later on the function of the device would be to drain out the aqueous humor in a 
way analogous to standard drainage devices. Following the surgical procedure the AGDD 
could be set into a functional closed position to minimize hypotony. Once the clinically 
relevant IOP is reached, the resistance to outflow could be adjusted accordingly. Critical 
aspects such as safety and efficiency of the AGDD were assessed in this first in vivo study. 
The rate of aqueous humor outflow was easily adjustable during the entire postoperative 
period based on the control of the outflow resistance of the AGDD between the fully closed 
and fully open positions. The surgical technique to implant the AGDD is comparable to the 
Ex-PRESS® procedure, demonstrating the simplicity and relative ease of use of the implant. 
These first in vivo results provided encouraging data on the safety and performance of the 
device. A human clinical trial will follow to demonstrate all aspects of safety, performance 
and efficacy of the AGDD in glaucoma patients. This will provide an effective means of 
controlling IOP during the initial post-op period on a per patient basis, in the aim to possibly 
minimizing the risk of hypotony in the early postoperative stages and to offer optimal IOP 
control during the entire post-operative period. 
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5.1 Introduction 
Age-related macular degeneration (AMD) is a leading cause1 of blindness in industrialized 
countries. However, the causes of this complex disease are not yet well understood. Genetics2 
and other risk factors, such as smoking, hypertension or elevated cholesterol,3,4 have been 
identified to have a role in the development of such disease. Among other causes, vascular 
factors also have been hypothesized to contribute to the onset of AMD pathophysiology.5,6 
Retinal imaging technologies, such as color Doppler imaging,7 laser Doppler flowmetry,8 and 
angiographic techniques,9 have shown abnormalities in the choroidal circulation by revealing 
reduced flow velocities and increased resistance indices in the central retinal artery of AMD 
patients. Several studies have reported that changes in ocular blood flow or in ocular vessel 
diameter can affect highly the development of the disease. Results of these studies support the 
hypothesis of an increase in choroidal vascular resistance due to a decrease in the ocular 
compliance.5,10 From that perspective, other studies demonstrated that the pulsatile amplitude 
of the blood flow pulse in retinal arteries was higher in the presence of AMD.11,12 Patients 
with AMD would likely have a stiffer, less compliant arterial vasculature feeding the eye, as a 
result of age-related degenerative changes in collagen and elastin.13 Furthermore, the elastin 
layer composing the Brunch’s membrane at the level of the macula, and the walls of large 
arteries analyzed in patients suffering from AMD was found to be thinner and more porous 
than that in controls.14 These observations would reinforce the relationship between AMD and 
the stiffening of systemic vessels. Consequently, it seems that there probably should be a 
relationship between some cardiovascular diseases affected by low arterial compliance and 
AMD. 
Therefore, it is of interest to develop methodologies for noninvasive or minimally invasive 
monitoring of the compliance of the eye vessels, as this may prove useful in diagnosing 
retinal diseases, such as AMD. The purpose of our study was to develop and test a new 
methodology to assess the compliance of the eye vessels based on physiological parameters 
and biomechanical properties of the eye, specifically the intraocular pressure (IOP), arterial 
pressure, and ocular rigidity of the eyeball. 
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5.2 Materials and Methods 
5.2.1 Mathematical model 
The model developed in this study is based on the pressure-volume relationship of the eye and 
the ocular arteries. Volume compliance is defined by C=ΔV/ΔP where ΔV is the change in 
volume for a given change in pressure (ΔP). Equation (1), below, defines the compliance for 
the arterial network (subscript a) and the eye (subscript e), respectively. Ce, in particular, 
defines the compliance of the entire eyeball, (combination of sclera and cornea). 
  and       (1) 
During the heart cycle, pulsatile imbalances of blood into and out of the eye lead to changes 
in the volume of blood within the ocular space. Similarly, imbalances in aqueous production 
and aqueous outflow may create volume fluctuations, but in the short time scale of a single 
heartbeat such imbalances in the production and outflow of aqueous humor are assumed to be 
negligible. Hence, the variation in ocular volume during the heart beat is identical to blood 
volume variation, so that  
      (2) 
These volume variations are related to changes in arterial and ocular pressure via their 
corresponding volume compliances: 
      (3) 
From eqs (2) and (3) we obtain the following simple relation between changes in volume of 
the heartbeat and the volume compliances of eye and ocular vascular bed 
                                                             (4) 
Ca =
ΔVa
ΔPa
Ce =
ΔVe
ΔPe
ΔVa = ΔVe
ΔVa = CaΔPa
ΔVe = CeΔPe
CaΔPa =CeΔPe
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which permits the estimation of intraocular vascular bed compliance Ca based on estimated of 
eye compliance Ce and measurements of intraocular and arterial pressure variations.
 
      (5) 
5.2.2 In vitro study 
Six freshly enucleated eyes (post-mortem time less than 4h) from white New Zealand rabbits 
were obtained from a local farm. The eye was held on a brace and the anterior chamber was 
canulated with a 24G catheter (Optiva® W, Smiths Medical, Rossendale, UK) filled with a 
saline solution. The catheter was placed between the anterior plane of the iris and the inner 
surface of the cornea. This perfusion set-up was connected to an electronic pressure 
transducer (BLPR2, World Precision Instruments, FL, USA) by a stopcock to measure the 
IOP corresponding to ΔPe (eq. 1). 
A 3F Forgarty artery embolectomy catheter balloon (Fogarty®, Edwards Lifesciences™, CA, 
USA) was used to induce volume changes within the eye, mimicking the volume changes of 
the vascular network of the eye during a heartbeat. The catheter was inserted in the posterior 
chamber and connected to a microsyringe pump (SP210iw, World Precision Instruments, FL, 
USA) filled of a saline solution. The volume of the balloon was changed periodically and at a 
rate of 1-2 Hz producing variations in intraocular volume in the range of 10 to 20 µl. These 
variations in volume correspond to ΔVa in eq. 1 and are accompanied by changes in pressure 
(ΔPa, eq.1) in a range of 150 to 350 mmHg. 
The perfusion set-up was connected to a data acquisition card (DAQPad-6015, National 
Instruments, TX, USA) that collected and displayed the signals using a custom made 
LabView interface (National Intruments, TX, USA). The IOP and balloon pressure were 
measured in this experiment, whereas the compliance of the eyeball (Ce, eq.1) was determined 
Ca = Ce
ΔPe
ΔPa
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in a companion experiment as described below. The compliance of the balloon (representing 
the compliance of the vascular network of the eye, Ca, eq. 1) was estimated experimentally 
based on relation (5) using data of IOP, balloon pressure and compliance of the eyeball  (this 
method was defined as the indirectly measured compliance). The indirectly measured balloon 
compliance was compared to balloon compliance estimated directly from pressure-volume 
obtained from the differential volume injected in the balloon and the corresponding change in 
intra-balloon pressure (Figure 5-1). 
 
Figure 5-1: Estimation of the compliance of the Fogarty balloon. In the direct method, the volume of the balloon was changed periodically 
(ΔVa) and the resulting pressure (ΔPa) was measured with a pressure transducer. In the indirect method, changes of ΔVa produced variations 
in intraocular volume (ΔVe) resulting in changes in intraocular pressure (ΔPe). The compliance of the eyeball (Ce) was determined with a 
companion experiment involving the measurement of the outflow facility. 
5.2.3 Eyeball compliance 
The eyeball compliance was calculated from outflow facility using the method described by 
Pallikaris et al17. In brief, the IOP was artificially increased and recorded from 10 to 25 
mmHg using a micropump at a rate of 100 µl/min. The net volume into the eye was estimated 
by subtracting outflow from inflow, the outflow being estimated from the outflow facility, as 
explained in the following paragraph. The eye compliance was then determined as the ratio of 
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the net volume of the eye and the increase in IOP. For calculation individual-specific eyeball 
compliance was used. 
The outflow facility is used to determine the eyeball compliance in both the in vitro and in 
vivo experiments. Details of outflow facility measurement have been previously reported15, 16. 
Briefly, the anterior chamber was perfused at first with a defined flow rate (2 µl/min). After a 
stable IOP level was reached, the flow rate was changed to a higher value until another stable 
IOP level was reached. The value of the change in flow rate divided by the IOP change 
measured represents the outflow facility (OF). The outflow facility is thus calculated using 
the Goldman equation 
OF = ΔQ/ΔIOP (ΔQ = (Q2-Q1))    (6) 
where Q1 and Q2 are successive inflow rates (µl/min), ΔIOP = (P2-P1), where P1 and P2 
represent IOP at Q1 and Q2 respectively (mmHg). 
In vivo study 
Five white New Zealand rabbits (3.5-4.5 kg) were used for this study. General anesthesia was 
performed using a mixture of a 3 mg/kg (body mass) Xylasine and a 35 mg/kg Ketamin 
intramuscular injection. Under general anesthesia, the central ear artery was canulated using a 
24G catheter (Optiva® W, Smith Medical, Rossendale, UK) and a 1 French Gauge diameter 
intra-arterial pressure guide (ComboWire®, Volcano, CA, USA) was inserted through the 
24G catheter. Systolic, diastolic and blood pressures were measured using the intra-arterial 
pressure guide at a rate of 100 Hz and the arterial pulse pressure amplitude was measured 
taking the diastolic-systolic pressure difference. The pressure sensor was located at about 10 
cm from the heart.  
Using the same type of Optiva® W catheter the anterior chamber of the eye was cannulated to 
measure the IOP after the lids were kept open using a wired lid speculum. The catheter was 
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connected to a pressure sensor (BLPR2, World Precision Instruments, FL, USA). Intraocular 
pressure was kept in the range of 10 to 25 mmHg to be close to physiological pressure values. 
Mean arterial pressure and IOP amplitude were acquired to establish baseline conditions. 
Then, Norepinephrine (10 µg/bolus) was administrated intra arterially and the mean arterial 
pressure and IOP amplitude were acquired. The eyeball compliance was determined before 
and after norepinephrine injection. The compliance of the vascular network of the eye was 
calculated using the IOP amplitude, the pulse pressure amplitude and the eyeball compliance 
before and after norepinephrine injection. After acquiring data on one eye, the second eye was 
canulated the same way and the same experimental procedure was followed. At the end of the 
experimentation the animal was sacrificed with a 120 mg/kg Pentobarbital intra arterial 
injection. All the experiments conformed to the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research and were reviewed and approved by the institutional 
committee for animal studies in Lausanne, Switzerland.      
5.2.4 Statistics 
The results were expressed as the mean and standard deviation (mean ± SD). The paired 
Student’s t-test was used to assess significant differences and effects of norepinephrine 
administration on the results. P < 0.05 was considered statistically significant.  
5.3 Results 
5.3.1 In vitro study 
The outflow facility was 0.35 ± 0.07 µl/mmHg·min and the compliance of the eyeball was 
equal to 14.13 ± 4.03 µl/mmHg (Table 5-1).  
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Table 5-1: Summary of the In Vitro Fogarty Balloon Compliance Measurements 
 
Variations in pressure of the Fogarty balloon, from 150 ± 10 mmHg to 350 ± 37 mmHg 
resulted in IOP variation from 0.6 ± 0.1 mmHg to 3.2 ± 0.4 mmHg. 
Results of the estimation of compliance of the Fogarty balloon using both direct and indirect 
methods are depicted in Table 5-1. Direct and indirect estimates of balloon compliance were 
0.075 ± 0.017 and 0.077 ± 0.021 µl/mmHg, respectively. The mean ratio between the directly 
and indirectly measured compliances was 0.99 ± 0.05, suggesting there is no significant 
difference between the two methods (p = 0.86) (Figure 5-2).  
 
Figure 5-2: Compliance of the Fogarty balloon. Bland-Altman graph comparing the indirect and direct estimates of balloon compliance. 
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5.3.2 In vivo study 
The mean outflow facility of the 10 rabbit eyes was equal to 0.209 ± 0.09 µl/mmHg·min. 
Norepinephrine increased the mean arterial pressure by 70%, an effect that was highly 
significant compared to the baseline (p < 0.001) (figure 5-3A). As expected this increase in 
mean arterial pressure was accompanied by 60% increase (p < 0.001) in arterial pulse 
pressure amplitude (figure 5-3B). The mean ocular pulse pressure amplitude (IOP pulse) 
increased after NE administration from 1.21 mmHg (± 0.24) to 1.55 mmHg (± 0.2) (p < 0.05, 
figure 5-3C). Finally, the arterial compliance significantly decreased after administration of 
NE from 0.18 µl/mmHg (± 0.12) to 0.10 µl/mmHg (± 0.08) (p < 0.05, figure 5-3D).   
Eye compliance was significantly reduced after NE injection (p < 0.05) with compliance 
being equal to 4.07 ± 1.49 µl/mmHg and 2.93 ± 1.48 µl/mmHg before and after injection, 
respectively (figure 5-3E). 
5.4 Discussion 
We have developed a new method to predict the compliance of the vascular network of the 
eye. Based on the principle of continuity and the variations of IOP and arterial pressure over 
the cardiac cycle, we have derived a simple relation which gives the compliance of the 
vascular network of the eye, Ca, as the product of eyeball compliance, Ce, times the ratio of 
IOP variation over arterial pulse pressure (ΔPe/ΔPa). The eyeball compliance was 
characterized in a parallel experiment following the outflow facility measurements. 
An in vitro approach, where a Fogarty catheter with a compliant balloon simulating the 
compliance of the ocular vessels was inserted in enucleated rabbit eyes, was used to validate 
the proposed model. The experiment showed that inflation of the Fogarty catheter induced an 
increase of the IOP. The results showed that the compliance of the Fogarty catheter balloon 
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can be predicted using our formula (Eq 5) quite precisely, with the average error being 
statistically insignificant and always less than ± 5% (Table 5-1).  
 
Figure 5-3: Effects of norepinephrine on the arterial pressure amplitude (A), mean arterial pressure (B), IOP pulse (C), arterial compliance 
(D), and ocular compliance (E). Data are presented as means and SD values. P values are calculated from paired t-tests comparing baseline 
data with data after administration of norepinephrine. 
 
After validating the model in vitro, we performed animal experiments to determine the 
compliance of the vascular system of the eye under control conditions and after 
administration of norepinephrine. Norepinephrine is a hormone that causes strong arterial 
vasoconstriction18. Consequently, the mean arterial pressure and arterial pressure amplitude 
have increased significantly, as expected19. According to the results obtained in this study, the 
arterial compliance has significantly decreased meaning that elevation of the systemic blood 
pressure changed the effective elastic properties of the arterial system. These findings are 
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plausible, as we expect that contraction of vascular smooth muscles (VSM) and increase in 
pressure would lead to decrease in vascular compliance20.  
Ocular compliance is a physical parameter of the eye that expresses the elastic properties of 
the eyeball upon inflation21. Based on observations by Langham et al.22, the coefficient of 
ocular compliance reflects the elastic properties of the sclera and the cornea in cadaveric eyes, 
where no blood circulation prevails. In contrast, when measured in vivo on animal models, 
ocular rigidity seems to be affected by ocular blood volume. In our study, the coefficient of 
ocular compliance was higher in enucleated eyes (14.13 µl/mmHg) compared to living eyes 
(4.07 µl/mmHg). We postulate that the blood circulation and the resulting vascular tone could 
have possibly contributed to the observed increase in the eye rigidity. It is worth mentioning 
that the ocular compliance, Ce, which is needed to calculate the intraocular vascular 
compliance, cannot be obtained noninvasively. Our in vivo measurement of the pressure-
volume relation of the rabbit eyeball were in accordance with the results presented by 
Kymionis et al.23, who evaluated the ocular rigidity of 16 rabbit eyes after photorefractive 
keratectomy. Dastiridou et al.24 studied the pressure-volume relation in the living human eye 
and found that the pulsatile change in IOP is directly related to the rigidity of the ocular layers 
that dampen the pulsations. The latter suggests that higher ocular pulse amplitude may be 
found in eyes with increased rigidity, due to either a higher rigidity coefficient or a higher 
IOP. In our study administration of NE increased the coefficient of ocular rigidity raising the 
ocular pulse pressure amplitude. This observation consolidates the statement made by 
Dastiridou and colleagues. 
Results from in vivo experiments have shown that NE significantly altered not only the 
compliance of the vascular network in the eye, Ca, but also the elastic properties of the eyeball, 
Ce. This could possibly suggest that decrease in compliance of ocular vessels leads to a more 
rigid and less compliant eyeball. Previous studies have shown that both ocular and vascular 
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compliance of the eye are affected by retinal disease. Friedman and associates10 have 
suggested that ocular rigidity plays a role in the development of AMD. They stated that the 
coefficient of scleral rigidity of age-related macular degeneration patients was higher than that 
of controls meaning that a more rigid sclera would likely alter compliance of vessels 
embedded in a less compliant surrounding. Later Pallikaris et al.25 also measured the ocular 
rigidity in patients suffering from AMD, distinguishing between the different types of AMD. 
Their results draw conclusions comparable to Friedman as they showed that the eye rigidity 
data were significantly higher in presence of neovascular AMD in comparison with the non-
neovascular form and the group of control patients. Sato et al.11, 12 stated that patients with 
AMD have a less compliant arterial network in the eye. They showed that the pulse wave 
velocity and the pressure associated with the central aortic blood pressure waveform were 
higher in patients with AMD compared to controls12 implying that an increase in vascular 
rigidity would lead to a stiffer scleral wall. All these findings suggest that AMD may be 
associated with increased vascular and eye rigidity. As stated before Friedman and Pallikaris 
suggested that an increasingly rigid sclera would affect the arterial compliance, encapsulating 
the ocular vasculature in a less compliant compartment. However, in our study we have 
demonstrated that a deliberate increase in the systemic arterial rigidity resulted in a 
corresponding elevation of the eye rigidity (Figure 5-3E). Consequently, we could suggest 
that a stiffer ocular arterial network could result in stiffer eyeballs. We may further add that 
the parameter Ca (arterial compliance) should be considered as a component of the overall 
eyeball compliance Ce. That is, Ca reflects not only the compliance of the vessel branches 
within the posterior chamber, but also incorporates the choroidal vasculature and intra-scleral 
vasculature. Hence, modifying the stiffness of this extended vasculature would necessarily 
impact overall eyeball stiffness, as they are inter-related. When considering previous studies 
on age-related macular degeneration and eyeball rigidity, a question remains unresolved: are 
the AMD-related haemodynamic abnormalities the result of an increase in the scleral rigidity, 
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or would elevation of the systemic vascular stiffness lead to further scleral rigidity?  Further 
studies are needed to clarify this question. 
In conclusion, we have proposed a method to estimate the compliance of the ocular vascular 
network, based on measurements of eyeball compliance, IOP and arterial pressure. The 
stiffness of the arterial network in the eye may be an important factor in the initiation and 
development of retinal disease. Age-related macular degeneration is a good example of how 
abnormalities in elastic properties of the choroidal blood vessels can alter the structure of the 
retina and ultimately the sight. Further studies should include human subjects to assess the 
link between changes in ocular vascular network compliance to retinal disease such as AMD.  
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The lack of IOP control over time remains one of the main problems in the management of 
glaucoma. Many of the complications related to glaucoma filtering surgery are linked to a 
lack of prediction of the IOP level achieved and maintained. Motivated by the drawbacks of 
the current procedures and devices used in glaucoma filtering surgery as well as their 
complications, a new non-invasively adjustable glaucoma drainage device has been developed. 
This implant aims at providing a viable solution to current glaucoma drainage devices adding 
an additional feature, which is an adjustable flow resistor. In that prospect, the purpose is to 
minimize the early post-operative hypotony and to control the evolution of the IOP by 
selectively changing the resistance to aqueous humor outflow. 
Hypotony is a common problem found in all glaucoma filtering procedures, often leading to 
further complications. The implant developed in this thesis aims at reducing the risk of post-
operative hypotony by increasing the resistance to aqueous outflow in the early post-operative 
stages. Thanks to its internal mechanism, the AGDD allows changes in the cross-sectional 
area of a draining tube, and thus adjustment in the resistance to flow. Considering the 
progressive nature of the scarring tissue and the wound healing response after implantation, it 
is anticipated that the ‘valve’ should be set at a relatively closed position during the early 
post-operative period to be progressively opened later on, maintaining optimal IOP level 
during the entire postoperative period.  
The different tests conducted during this study have demonstrated the efficacy and the ease of 
use of the AGDD through in vitro and in vivo experiments. The adjustability of the device has 
been shown to be reproducible, however the range of adjustment between the functional fully 
open position to the fully closed position offers a rather small range of manageability 
(approximately 50 degrees or 4 to 5 functional positions). The range of adjustment has to be 
increased in order to offer a larger operational range for the clinicians. The procedure of 
implantation has demonstrated some similarities to conventional filtering surgeries such as the 
implantation of the Ex-PRESS® or even trabeculectomy. This kind of surgery is comparable 
to standard procedures performed by eye surgeons.  
Extensive series of tests (biocompatibility, sterility, bioburden, etc.) according to applicable 
regulatory standards have been carried out successfully, allowing for the CE marking of the 
device and validating the safety of the device for human implantation. Naturally, the materials 
used for the assembly of the AGDD are certified as biocompatible and safe for human use. 
However, further investigations still need to be conducted on humans to assess the safety, 
performance and efficacy of the device, especially at the long-term.  
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In this thesis the AGDD has been always described as a stand-alone device. Nonetheless, the 
design of the implant offers some innovative options, e.g. the connection to a seton tube has 
been foreseen for further draining possibilities. That way the drainage of the aqueous humor 
does not occur under the sclera next to the limbus, but takes place rather far under the 
subconjuctival in the equatorial region of the eyeball. Fibrous response should therefore 
develop on a much less extent as compared to what prevails closer to the limbus, thus 
enhancing the rate of success. In addition, the connection could even be extended to a further 
point, reaching the orbit of the eye, where fibrosis formation would be minimal. 
Perspectives 
The next objective for the AGDD is the performance of human clinical trials. Safety, 
performance and efficacy will be tested, providing a refined answer on the clinical benefits 
and advantages that the implant may offer. Future clinical trials should not only test the 
device itself but also the kind of procedure used for the implantation. We may thus assert 
whether the AGDD could be placed as a stand-alone device or in combination with a seton 
tube. Both procedures should be carefully tested in order to enlarge the field of application of 
the AGDD. 
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